

Proposal to Modify the Adult Heart Allocation System

OPTN/UNOS Thoracic Organ Transplantation Committee

*Prepared by: OPTN/UNOS
UNOS Policy Department*

Executive Summary	1
Is the sponsoring Committee requesting specific feedback or input about the proposal?	2
What problem will this proposal solve?	3
Why should you support this proposal?	4
Which populations are impacted by this proposal?	23
How does this proposal impact the OPTN Strategic Plan?	24
How will the OPTN implement this proposal?	24
How will members implement this proposal?	26
How will members be evaluated for compliance with this proposal?	27
How will the sponsoring Committee evaluate whether this proposal was successful post implementation?	27
Policy or Bylaws Language	30

Proposal to Modify the Adult Heart Allocation System

Affected Policies: Policy 3.7.B: Required Expedited Modifications of Waiting Time, Policy 6.1: Status Assignments and Update Requirements, Policy 6.1.A: Adult Heart Status 1A Requirements, Policy 6.1.B: Adult Heart Status 1B Requirements, Policy 6.1.C: Adult Heart Status 2 Requirements, Policy 6.2: Status Updates, Policy 6.3: Adult and Pediatric Status Exceptions; Policy 6.3.A: RRB and Committee Review of Exceptions, Policy 6.3.B: Exceptions to Allocation for Sensitized Candidates, Policy 6.4: Waiting Time, Policy 6.5.C: Sorting Within Each Classification, Policy 6.5.D: Allocation of Hearts from Donors at Least 18 years Old, Policy 6.5.E: Allocation of Hearts from Donors Less Than 18 Years Old, and Policy 6.5.F: Allocation of Heart-Lungs

Sponsoring Committee: Thoracic Organ Transplantation

Public Comment Period: August 15, 2016 – October 15, 2016

Executive Summary

The Thoracic Organ Transplantation Committee (the Committee) proposes modifications to the adult heart allocation system to better stratify the most medically urgent heart transplant candidates, reflect the increased use of mechanical circulatory support devices (MCS) and prevalence of MCS complications, and address geographic disparities in access to donors among heart transplant candidates. In response to significant comments received during the first round of public comment, and based on additional feedback and consensus-building after public comment, the Committee proposes the following modifications to the original proposal:¹

- Refining and tightening the qualifying criteria for candidates supported by veno-arterial extracorporeal membrane oxygenation (VA ECMO), percutaneous circulatory support devices, intra-aortic balloon pumps (IABP), and multiple inotropes to require evidence that these candidates are supported by these therapies for treatment for cardiogenic shock, rather than qualifying based on the presence of the therapy alone
 - Criteria for determining presence of cardiogenic shock are based on American Heart Association definitions or the presence of end-organ dysfunction
- Placing additional restrictions on the duration for candidates may remain in statuses 1 through 3
 - Candidates supported by the therapies above, which are intended for short-term, acute therapy for cardiogenic shock, will be limited to 14 days in the respective status unless the candidate exhibits contraindications to use of a durable device and has failed a weaning attempt
- Clarifying which mechanical circulatory support devices qualify a candidate for certain statuses, including limiting status 1 to candidates supported for biventricular failure with surgically-implanted, non-endovascular devices
- Requiring regional review boards to review cases external to their region
- Limiting the proposed broader geographic sharing scheme for the most urgent candidates to donation service area and Zone A (instead of through Zone B)
- Modifying the pediatric donor allocation sequence to limit potential negative impacts of the new adult heart allocation system on pediatric candidates

¹ A detailed comparison of the January 2016 proposal and the August 2016 proposal can be found in **Appendix A**.

Is the sponsoring Committee requesting specific feedback or input about the proposal?

1. Are the proposed indicators of cardiogenic shock appropriate?
2. Should regional review boards review cases from other regions instead of their own regions?
3. Should the current policy for sensitized candidates (permitting the transplant programs and OPO in the donation service area to agree to allocate a donor heart to a sensitized candidate even if the candidate is not first on the match run) remain in place in light of broader sharing?
4. Which data elements on the list of potential heart allocation score data are likely to be incorporated into a heart allocation score due to their potential to predict waiting list mortality or post-transplant survival? Are there additional data elements that should be collected which the Committee did not include? Are there extraneous data elements on the list? Are there any data elements that should only be collected on VAD patients?

What problem will this proposal solve?

Since the last significant revision to the adult heart allocation system in 2006, there has been an overall decline in waiting list mortality rates among adult heart transplant candidates, and specific patient groups intended to benefit from the previous policy changes experienced the most substantial decline in mortality rates. The Committee acknowledged the success of the 2006 policy modifications, but ultimately determined that there are candidate groups disadvantaged by the current system for various reasons, such as their diagnosis, the way their physician chooses to treat their condition, or because of geographic location. The Committee determined there are four major problems with the current system:

- 1) Too many candidates with disparate urgency risks in the most urgent status
- 2) Too many exception requests required
- 3) Current system does not accommodate increased use of MCSDs
- 4) Geographic sharing scheme is inequitable

Too Many Candidates in the Most Urgent Status

First, since 2006, the number of active heart transplant candidates more than doubled from 1,203 candidates on July 31, 2006 to 3,008 candidates on November 30, 2015. During that same time period, the number of status 1A candidates increased 548 percent, from 58 to 376, and the number of status 1B candidates increased 580 percent, from 255 to 1,734. By 2015, sixty-seven percent of adult heart transplants (2,347) were performed for patients that were status 1A at time of transplant. Candidates classified as status 1A are three times more likely to die on the waiting list than candidates in any other status, and also have vastly disparate waiting list mortality risks even within status 1A. The current system therefore requires stratification that is more granular in order to ensure that candidates in most need have access to donor hearts first.

Too Many Exception Requests Required

Second, some candidate groups, such as candidates diagnosed with amyloidosis or congenital heart disease, are not served well by the current system and often must request exceptions. Between July 2009 and June 2011, members submitted 640 status 1A exception requests on behalf of 400 candidates, and 310 status 1B exception requests on behalf of 255 candidates. Depending on exceptions is not optimal for the patient, because the submitting an exception request is a choice left to each transplant program which can lead to variability in practice, and exception requests must be approved by a regional review board, leading to the potential for variability dependent upon the region in which the request was made. The proposed policy better accounts for relative waiting list mortality rates of all candidate groups, including those candidates currently forced to apply for policy exceptions, and treats these patients more equitably.

Increased Use of MCSDs Not Accommodated by Current System

Third, medical practice in the heart transplant community has also evolved since 2006; use of MCSDs has increased significantly, though disparately depending upon geography. In 2007, only 8.9 percent of candidates were first registered under an MCSD-related criterion; by 2015, that percentage increased to 24.4 percent (and 34.5 percent of status 1A or 1B registrations). Increased use of MCSDs has occurred concurrently with changes in available technology and broadening of the patient population being supported. The devices and patients vary widely in risk, based on the severity of heart failure, the requirement for biventricular support, the type of MCSD being implanted, and the occurrence of complications. The proposed system better stratifies candidates based on the type of MCSD support and the risks associated with specific device complications.

Geographic Sharing Scheme is Inequitable

Lastly, in March 2000, the US Department of Health and Human Services (HHS) implemented the Final Rule, which instructs OPTN/UNOS allocation policies must, among other factors, be based on sound medical judgment, seek to achieve the best use of donated organs, and shall not be based on the candidate's place of residence or place of listing except to the extent needed to satisfy other regulatory requirements.² The current geographic sharing scheme favors less urgent candidates in the local DSA rather than more urgent candidates who may be as close as 25 miles away from the donor but are in Zone A. The proposed policy modifies the current geographic sharing scheme to ensure the most urgent candidates have access to donors in a broader geographic area.

Why should you support this proposal?

The proposed policy addresses the problems outlined above by better distinguishing and prioritizing candidates based on urgency and by reflecting the conditions of a wider range of heart transplant candidates than the current system. The proposal incorporates physiological principles into the criteria that were previously based on clinical consensus and subjective patient management decisions, and not clearly stated in policy. It also increases access to the donor pool for candidates most urgently in need of transplant. Most importantly, this proposal is expected to provide timely access to transplant for candidates most in need without negatively impacting candidates that may be able to wait longer for transplant.

This proposal also incorporates feedback from various stakeholders received during and after the first round of public comment in January 2016. To review feedback from different stakeholders and the Committee's response, see "**How was this proposal developed?**" below.

How was this proposal developed?

The current adult heart allocation system stratifies active candidates into three medical urgency statuses: status 1A; status 1B, and status 2. Candidates are considered adults if they are registered on the waiting list at age 18 years or older. Candidates qualify for status 1A, if:

- they require continuous infusion of a single high-dose intravenous inotrope or multiple intravenous inotropes and continuous hemodynamic monitoring
- they are supported by a total artificial heart, an intra-aortic balloon pump (IABP), extracorporeal mechanical oxygenation (ECMO), mechanical ventilation, or a ventricular assist device (VAD) (for a 30 day discretionary period)
- they are implanted with a MCS and are experiencing a device-related complication
- they have an approved exception

Candidates that are stable but supported by a VAD or that require continuous infusion of intravenous inotropes and do not meet the criteria for status 1A qualify for status 1B. Candidates that are in need of a heart transplant but do not meet status 1A or 1B qualifying criteria qualify for status 2.


Geographic allocation depends on the location of the donor. **Figure 1** demonstrates the zonal structure for allocation of thoracic organs. The donation service area (DSA) is the starting point, and is the geographic area designated by the Centers for Medicare and Medicaid Services (CMS) that is served by one organ procurement organization (OPO), one or more transplant hospitals, and one or more donor hospitals. The 58 DSAs are not uniformly shaped and differ substantially in terms of land mass, area, population, and number of transplant programs.

Zone A includes all transplant hospitals within 500 miles of the donor hospital but outside of the donor hospital's DSA; Zone B includes all transplant hospitals within 1,000 miles of the donor hospital but

² 42 C.F.R. §121.8

outside of Zone A and the donor hospital's DSA; Zone C includes all transplant hospitals within 1,500 miles of the donor hospital but outside of Zone B and the donor hospital's DSA; Zone D includes all transplant hospitals within 2,500 miles of the donor hospital but outside of Zone C; and finally Zone E includes all transplant hospitals more than 2,500 miles from the donor hospital.

Figure 1: Zones Used for Thoracic Organ Allocation



In the current allocation system, organs recovered from deceased donors aged 18 years or older are first offered to status 1A candidates “locally” within the donor hospital's DSA and then to status 1B candidates locally. If not accepted locally, the heart is then offered to status 1A candidates in Zone A, and then to all status 1B candidates in Zone A. Only after offers are made through Zone A status 1B candidates is the heart then offered to a local status 2 candidate. Allocation then continues through subsequent geographic zones.

Identifying Limitations of the Current Adult Heart Allocation System and Goals of Modifications

The Committee defined its goals in modifying the adult heart allocation system:

- 1) Reduce waiting list mortality rates
- 2) Reduce the use of exceptions to qualify for a status by better accommodating all candidate groups within the heart allocation system
- 3) Ensure that qualifying criteria for the statuses are based on objective physiological indications rather than therapeutic intervention
- 4) Improve overall access to transplantation in the heart allocation system by modifying geographic distribution to ensure maximum utility of donor hearts

To achieve the stated goals, the Committee debated three potential solutions:

1. Retain the current three-status system
2. Develop a heart allocation score
3. Develop additional statuses

The Committee considered retaining the current three-tiered system but refining the qualifying criteria for each of the statuses. This idea was quickly dismissed, because it is clear based on the number of exception requests and disparate waiting list mortality rates for candidates in status 1A that the adult heart candidate pool is too diverse to be stratified effectively by so few statuses.

In 2012, the OPTN/UNOS Board of Directors charged the Committee to “consider replacing the heart status system with a heart allocation score.”³ The Committee debated the merits of developing a heart allocation score (HAS). It acknowledged that a HAS may eventually be the best method for accounting for post-transplant survival and net benefit. However, the OPTN does not currently collect all the data necessary to develop an appropriate HAS at this time. Additionally, the Committee was concerned that the HAS is not a flexible solution, as gathering and evaluating data to update the score to reflect current practices and candidates takes time, and is also dependent on programming changes, which also take time. This would be particularly problematic for the heart transplant community, as technology is changing quickly and may affect the outcomes of subgroups of patients and invalidate the HAS. The Committee agreed that VAD technology in particular is evolving rapidly and may exceed the ability of a HAS to account for new devices and complications.

Based on these considerations, the Committee ultimately opted to develop additional statuses to better stratify heart transplant candidates while prospectively collecting additional data that may be necessary for developing a heart allocation score in the future, if the Committee decides to do so. The Committee agreed that adding more statuses to the current system may better accommodate the speed at which technology changes, because if a patient group is suddenly doing much better or much worse, moving those patients among the statuses can be done more quickly than changing a HAS system.

To plan for a heart allocation score, the Committee identified data that are likely to be predictive of waiting list mortality or post-transplant survival. These data are described in the “Will this proposal require members to submit additional data?” section below.

Development of Additional Statuses

To develop additional statuses, the Committee first compared the waiting list mortality rates and post-transplant mortality rates of all heart candidates in each criteria, with a particular focus on better stratifying candidates currently in status 1A.⁴

The Committee reviewed data that revealed that candidates in status 1A currently have the highest waiting list mortality rates and the highest post-transplant mortality rates, and are transplanted the most often. Moreover, waiting list mortality rates among status 1A candidates vary considerably by criteria. Six month waitlist mortality among status 1A candidates varied from 4.8% in those with MCSD with infection, to 5.1% in those with VAD for 30 days, to 35.7% in those with ECMO. Status 1A candidates supported by mechanical ventilation and ECMO had the highest waiting list mortality rates, while candidates with continuous hemodynamic monitoring supported by multiple inotropes or a single high dose inotrope, VAD candidates using discretionary 30 day status 1A time, and MCSD candidates with infection exhibited the lowest waiting list mortality rates of the status 1A candidates.

³ 2012-2015 OPTN/UNOS Strategic Plan

⁴ OPTN/UNOS Descriptive Data Request: “Outcomes for Adult Candidates and Recipients by Status 1A Criteria and Diagnosis.” Prepared for Heart Subcommittee Conference Call, March 12, 2013.

The Committee also compared risk based on candidates' diagnoses at listing and at transplant within each urgency status. These data reveal that status 1A candidates have widely disparate waiting list mortality risks. Waiting list mortality and post-transplant survival rates currently vary based on medical urgency status, criteria, and sub-criteria, and by diagnosis stratified by status.

The Committee also analyzed all status 1A and status 1B exception requests submitted for heart and heart-lung candidates between July 2009 and June 2011 to identify common categories of exception requests (Figures 2 and 3).

Figure 2: Categories for Adult Status 1A Exception Narratives (N=640)





Figure 3: Categories for Adult Status 1B Exception Narratives



The three most frequently reported categories represent over half of the exception requests in both status 1A and status 1B. For status 1A, the most common rationale provided for exception requests were: 1)

candidate is experiencing ventricular tachycardia or ventricular fibrillation; 2) candidate does not have intravenous access for inotropes or cannot tolerate a pulmonary artery catheter; and 3) congenital diagnosis. For status 1B, the most common rationale provided for exceptions request were: 1) candidate is experiencing ventricular tachycardia or ventricular fibrillation; 2) congenital diagnosis; and 3) candidate requires a re-transplant.

After reviewing these data, the Committee formulated a draft, or “straw man” version of the proposed statuses. The straw man statuses primarily grouped candidates together by similar waiting list mortality rates, but also considered post-transplant mortality risk, as well as Committee members’ experience with candidates in these groups.

After confirming the straw man groups, the Committee requested the SRTR perform a thoracic simulation allocation model (TSAM) to show the projected impact of the straw man statuses. The TSAM request was designed to mirror current allocation rules as closely as possible, including the intermingling of adult candidates and pediatric candidates, in order to verify that the modeled outcomes reflect the impact of the straw man itself, and not any other inadvertent changes to the allocation system. The results of this TSAM are described in the **“How well does this proposal address the problem statement?”** section below.

During the first round of public comment, some commenters expressed concern that by focusing on improving waiting list mortality rates, post-transplant outcomes may be negatively affected. For example, candidates supported by ECMO have very high waiting list mortality rates, but also tend to do worse post-transplant. In the supporting evidence section below, **Figure 10** reveals that one-year post-transplant survival rates are not expected to increase significantly if the proposed changes are adopted. However, commenters expressed concern that the modeling is based on current behavior and practices, and that the proposal would influence practitioners to behave differently than they currently do; doctors may be more likely to put their patients on ECMO in the future if it means their patients are more likely to receive an organ offer more quickly. More patients transplanted after being supported by ECMO may mean that the overall system would experience worse post-transplant outcomes.

The Committee took these concerns seriously. Ultimately, the Committee re-committed to its primary goal of reducing waiting list mortality rates, particularly for the most urgent candidates, and made the decision to keep candidates stratified in the same order as the previous proposal as supported by data and TSAM. However, in weighing whether to defer to clinical expertise, or instead to adhere strictly to the models and data, the Committee determined that in matters of behavior, it should defer to clinical expertise. Therefore, the Committee reached out to the community to gain clinical consensus to guide the establishment of restrictions for the qualifying criteria for the most urgent statuses to attempt to ward off unintended behavioral changes. The proposed restrictions are described in detail in the Detailed Definitions for Status Criteria below.

Development of Broader Sharing

Following a critical review of the TSAM data, the Committee was satisfied that patient subgroups were more accurately stratified and began considering improvements to the geographic sharing scheme. The Committee focused on an example that highlights a significant problem in the current system: if a donor heart becomes available in northern New Jersey, a status 1B heart candidate awaiting a heart transplant within the DSA in New Jersey would receive the organ offer before a status 1A candidate awaiting a heart transplant in Zone A in New York City, just 25 miles away. The Committee believes allocating in this manner violates the Final Rule, which states that, to the extent feasible while not compromising patient health or the health of the donor organ, the OPTN’s allocation policies “[s]hall not be based on the candidate’s place of residence or place of listing...”

The Committee determined that broader sharing of adult hearts to the most urgent candidates first, as well as minimizing the impact of “local” sharing based on DSA, may help to ensure that the candidates

most in need of transplant have access to the broadest range of available donors. The Committee debated which urgency statuses required the broadest sharing, as well as how far the first geographic allocation unit should be. Ultimately, the Committee determined that proposed statuses 1 and 2 should benefit from the broadest sharing, as these candidates are very urgent and would benefit most from exposure to more donors. The number of candidates that will qualify for proposed status 1 and status 2 is also relatively small and therefore will have a smaller impact on candidates waiting in other statuses. For example, the TSAM results reveal that of the transplants performed under the originally proposed broader sharing scheme, 5 percent were status 1 candidates, 22 percent were status 2 candidates, 36 percent were status 3 candidates, and 30 percent were status 4 candidates. The Committee reaffirmed its commitment to providing broader sharing to status 1 and 2 candidates after the first round of public comment, and this principle was supported by the community during the post-public comment consensus gathering process.

The Committee debated whether to eliminate local sharing altogether, thereby implementing Zone A (500 miles from the donor hospital) as the first geographic unit of allocation. Some members of the Committee believe that local sharing is based on arbitrary boundaries, thus violating the Final Rule. The Committee also recognized that some people reject the concept of minimizing or eliminating local sharing, asserting that people may be more willing to donate if they know their organs are going to be shared with their local community. However, there is no evidence to prove this assertion. Most people prefer their donated organs be allocated to the “more medically urgent patients regardless of where they live in the U.S.”⁵ and one study noted “the public tends to draw community lines at national rather than local boundaries.”⁶ Moreover, many donors and donor families are not familiar with the DSA boundaries, and may also therefore be unaware that a DSA boundary may indeed run through their community, rather than circumvent it. Nevertheless, the Committee determined the best compromise is to keep local sharing as the first geographic unit of allocation, but to combine it with Zone A, so that all urgent candidates registered locally and within Zone A are grouped together, rather than sequentially.

The Committee also weighed the candidates’ urgency against the safety of shipping organs further. If the first geographic unit were combined all the way out to Zone B (1,000 miles from the donor hospital), then outcomes might be less optimal because more urgent candidates would be transplanted with organs with longer cold ischemic time. However, the Committee also acknowledged that an organ with a longer ischemic time may be appropriate for very urgent candidates, and a preferable strategy to waiting for a local donor organ. As a compromise in the original proposal, the Committee determined that the most urgent candidates in the DSA and Zone A should have the first opportunity, *then* urgent candidates in Zone B.

During and after the first round of public comment, some members of the community expressed concerns that sharing to Zone B for the sickest patients may negatively affect post-transplant outcomes. The TSAM results, modeling the potential impact of various broader sharing schemes described in the “How well does this proposal address the problem statement?” section below, do not support the assertion that post-transplant outcomes will be significantly worse if broader sharing is adopted. In response, the Committee reexamined the TSAM results and determined that there will still be substantial improvement in transplant rates for status 1 and 2 candidates even if geographic sharing for status 1 and 2 patients is limited at first only to the DSA and Zone A, which may in turn reduce the number of deaths on the waiting list. Therefore, in the revised proposal the Committee puts forth that broader sharing should initially extend only to status 1 and 2 candidates in the DSA plus Zone A. Status 1 and 2 candidates in Zone B will receive offers only after status 3 candidates in the DSA. This compromise ensures that high urgency candidates in a reasonably broad geographic area have equitable access to organ offers, while

⁵ <http://organdonor.gov/dtcp/nationalsurveyorgandonation.pdf>

⁶ M. L. Volk, G. J. W. Warren, R. R. Anspach, M. P. Couper, R. M. Merion, P. A. Ubel. “Foreigners Traveling to the U.S. for Transplantation May adversely Affect Organ Donation: A National Survey.” *American Journal of Transplantation*: 2010; 10: 1468-1472. DOI: 10.1111/j.1600-6143.2010.03111.x

minimizing the potential increase in donor organ ischemic times (and possible consequent worsening of post-transplant outcomes).

The Committee also realized that the pediatric donor sequence in the original proposal may negatively impact some pediatric patients, despite the Committee's intention to leave pediatric donor allocation largely unchanged. The goal of the original proposal was to minimize the impact, or provide a positive impact, on allocation of donor hearts to children. The primary mechanism for doing so was to equate status 1A pediatric candidates with status 1 adult candidates, status 1B pediatric candidates with status 3 adult candidates, and status 2 pediatric candidates with status 6 adult candidates. Consistent with current allocation policy, offers from pediatric heart donors would be made to pediatric candidates ahead of adult recipients at the equivalent status and in the same geographic range, while equivalent pediatric and adult candidates in the same geographic range would be grouped together for offers from adult heart donors. Because new status 1 adult candidates are the subset of current status 1A adult candidates with highest waitlist mortality, and new status 3 adult candidates are the subset of current status 1A adult candidates with the lowest waitlist mortality, the Committee believed this scheme would benefit pediatric candidates and increase the availability of both adult and pediatric donor hearts to pediatric candidates at both status 1A and 1B.

Despite these intentions, there was significant public comment received regarding the potential for a negative impact on allocation to children, particularly in light of recent changes to pediatric allocation policy. Under new pediatric heart allocation policy, pediatric status 1B candidates are expected to rise in number, while fewer candidates will qualify for pediatric status 1A. Unfortunately, under the original proposed policy, while most of the impact on pediatric recipients resulted in earlier and therefore more beneficial allocation to pediatric candidates, allocation to pediatric status 1B candidates in Zone A would be negatively impacted, with allocation occurring to the following groups first: adult status 1 or 2 candidates in the donor's DSA, Zone A, or Zone B, and adult status 3 and 4 in the donor's DSA. While the allocation to adult status 1 or 2 is not expected to have a large impact due to the small number of candidates in those statuses, there is expected to be a large number of adult status 4 candidates, potentially significantly impacting allocation to 1B pediatric recipients in Zone A.

The Committee confirmed the significant potential negative impact on pediatric status 1B recipients, and determined it should revise the proposed pediatric donor allocation sequence to eliminate potentially negative impacts. Because the current allocation policy change is directed primarily at adult candidates, the new policy should leave pediatric donor heart allocation unchanged to the extent possible. The current proposal aims to eliminate the negative impact on allocation to pediatric 1B recipients and to leave the current balance of geographic sharing within pediatrics unchanged. The revised proposal limits broader sharing to Zone A, which also mitigates some of the negative impact on pediatrics.

Detailed Definitions for Status Criteria

The TSAMs projected the outcomes of heart candidates based on the straw man groups. However, as the Committee developed the proposal, it became clear that the candidates that qualify for a status should be more specifically defined, by physiological parameters when possible, to ensure that the status comprises the patients that are truly urgent. Feedback received from the Forum on U.S. Heart Allocation Policy in November 2013⁷ and a forum hosted by the American Society of Transplantation (AST) in May 2015 emphasized that the definitions for the candidates that qualify for each status should be very clear.

The Committee sought additional clinical input for establishing the parameters for each of the status criteria during and after public comment. Committee members led and participated in discussions at

⁷ J. A. Kobashigawa, M. Johnson, J. Rogers, J. D. Vega, M. Colvin-Adams, L. Edwards, D. Meyer, M. Luu, N. Reinsmoen, A. I. Dipchand, D. Feldman, R. Kormos, D. Mancini¹¹ and S. Webber on behalf of the forum participants. Meeting Report: Report from a Forum on US Heart Allocation Policy. *American Journal of Transplantation* 2015; 15: 55–63. doi: 10.1111/ajt.13033.

various forums, including at the Cutting Edge of Transplantation conference hosted by AST in February 2016, the International Society of Heart & Lung Transplantation (ISHLT) annual conference in April 2016, and the American Transplant Congress (ATC) in June 2016.

Additionally, the Committee distributed a survey developed to elicit additional feedback on how to revise policy with regard to geographic sharing, and candidates supported by VA ECMO, acute circulatory support devices, and LVADs. The survey was distributed to OPTN heart transplant program administrators and program directors, OPO executive directors, and the following OPTN/UNOS OPO, Pediatric, Transplant Coordinator, Transplant Administrator, and Minority Affairs Committees. The link was also posted on the ISHLT blog. The survey was open from June 13 through June 24, 2016, and the Committee received 169 responses.

Consensus largely supports creating additional qualifying criteria for the most urgent statuses, and establishing a higher level of review for extending urgent statuses for candidates that are supported by therapies intended to be temporary. The Committee proposes imposing additional criteria for initially qualifying for status 1 under the VA ECMO criterion, status 2 under the percutaneous device and intra-aortic balloon pump criteria, and status 3 under the multiple inotropes with hemodynamic monitoring criterion. The proposal requires that these therapies are being used to treat cardiogenic shock.

Participants at the ISHLT annual conference suggested the Committee adopt the American Heart Association (AHA) definition of cardiogenic shock.⁸ The Committee therefore proposes that, from a hemodynamic assessment within 7 days prior to administration of these therapies, the candidate's systolic blood pressure is less than 90 mmHg, pulmonary capillary wedge pressure is greater than 15, and cardiac index is either less than 1.8 L/min/m² if the candidate is not supported by inotropes or less than 2.2 L/min/m² if the candidate is supported by inotropes. For those candidates whose hemodynamic measurements cannot be obtained within 7 days prior to support, then within 24 hours prior to support either the candidate's systolic blood pressure must be less than 70 mmHg, arterial lactate must be greater than 4 mmol/L, aspartate transaminase (AST) or alanine transaminase (ALT) must be greater than 1,000 U/L, or CPR must have been performed on the candidate.

The Committee debated how long the initial qualifying period should last for each of these criteria. The Committee considered shortening the initial period to 7 days, particularly for VA ECMO and percutaneous circulatory support devices, because the community generally agrees that these therapies should not be used for a period longer than 7 days. The results of the TSAM demonstrate that on average the 50-55 patients ever on ECMO included in the TSAM cohort were supported by ECMO for between 2 to 4 days.⁹ However, data show that 15 percent of candidates were supported by these therapies longer than 7 days. Within the TSAM cohort, under the proposed sharing scheme ("6 urgency statuses with broader sharing") described in the "How well does this proposal address the problem statement?" section below, the maximum number of days a candidate was supported by ECMO is 8. Additionally, the survey results supported permitting these candidates to be registered in their respective statuses for 14 days. The Committee ultimately determined that the 14 day initial period is appropriate, but decided to establish stringent criteria for extending a candidate's registration in these statuses beyond the initial 14 day period.

There is consensus that, after a period of 14 days, the decision to continue supporting a candidate with a temporary therapy (VA ECMO, acute circulatory support devices, intra-aortic balloon pumps, and non-dischargeable left ventricular assist devices (LVADs)) often becomes a choice rather than a necessity. The community criticized the original proposal for incentivizing practitioners to leave their candidates on temporary support for longer than clinically indicated solely to grant their candidates access to the higher statuses. Participants at the ISHLT annual conference and the survey responses also largely supported establishing a higher level of review for extending the high urgency statuses related to temporary support.

⁸ Reynolds, H.R. and Hochman, J.S. Cardiogenic Shock: Current Concepts and Improving Outcomes. *Circulation*. February 5, 2008. <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.613596>

⁹ Skeans M and Audette K. Memorandum: Simulated time spent using selected heart status criteria. June 27, 2016.

Therefore, the Committee proposes requiring transplant programs to apply to the regional review boards (RRBs) to extend a candidate's registration after their initial period if they are supported by VA ECMO, acute circulatory support devices, non-dischargeable LVADs, or intra-aortic balloon pumps. The transplant program must provide the RRB with evidence that the candidate has a contraindication to being transitioned to durable support, and objective evidence of a failure to wean the candidate off the current support. The proposal specifies precisely the evidence the transplant program must provide the RRB.

If the candidate remains supported by these therapies but the RRB either does not grant an extension or the transplant program does not request one, the Committee proposes these candidates qualify for status 3. The Committee believes status 3 is an appropriate status, because the candidates continue to have a wait list mortality risk comparable to others in the high urgency statuses, but in status 3 they will no longer have access to broader sharing. This ensures that the candidates are appropriately stratified based on risk while removing an incentive to continue what is generally believed to be more temporary therapy.

Changes to other qualifying criteria are detailed below. If a subcriterion is not mentioned below, then the revised proposal does not include significant changes than were included in the original proposal.

Status 1

- Status 1: Continuous Mechanical Ventilation

The Committee debated whether continuous mechanical ventilation should remain in policy. Committee members noted that continuous mechanical ventilation is not usually an indication for heart transplant, and, like ECMO, these candidates may have a higher post-transplant mortality. The Committee reviewed data regarding the number of transplant recipients that were registered as status 1A under the continuous mechanical ventilation criterion at the time of their transplant. Between 2012 and 2014, over 420 patients used continuous mechanical ventilation as status 1A criteria at least once, and about 20 patients per year

received transplants while registered as status 1A with continuous mechanical ventilation as the justification.¹⁰

Though the Committee included continuous mechanical ventilation in the original proposal, it proposes removing continuous mechanical ventilation as a justification for status 1 in the revised proposal. The Committee reiterated that continuous mechanical ventilation is not an indication for heart transplantation, and candidates currently registered using continuous mechanical ventilation are likely to have collinear therapies that will qualify the candidates for other statuses.

- Status 1: Non-Dischargeable VADs

The Committee proposes re-naming this status criterion to “Surgically Implanted, Non-Endovascular Biventricular Support Devices.” The original proposal permitted anyone supported by a device that was not approved for use outside of the hospital by the U.S. Food & Drug Administration (FDA) to qualify for status 1. This proposal limits this criterion only to *biventricular* support devices that are not approved for use outside the hospital, and is intended to apply to those candidates whose devices were placed after undergoing a thoracotomy or median sternotomy. The revised proposal also creates a status criterion in status 2 for those candidates supported by LVADs that are not FDA-approved for use outside the hospital.

Status 2

- Status 2: Total Artificial Heart (TAH), Dischargeable Right Ventricular Assist Device (RVAD), BiVAD, or Single Ventricle Patients with LVAD

The revised proposal combines the TAH criterion and RVAD, BiVAD, and single ventricle LVAD criteria into one, but otherwise does not change the rules for qualifying for this status.

- Status 2: Acute Circulatory Support (ACS) Device

The Committee proposes re-naming this criterion “Percutaneous Endovascular Mechanical Circulatory Support Device.” The name change is intended to clarify exactly which devices would qualify a candidate to be registered under this criterion. The Committee also proposes including in the definition the term “without an oxygenator” to clarify that ECMO is not the type of support envisioned to qualify for this status. Like ECMO, the revised proposal includes strict criteria to qualify using this justification for status 2, and also adopts the stricter extension criteria described above.

- Status 2: Intra-aortic Balloon Pump (IABP)

IABP is another therapy that is at risk for being used simply to qualify a candidate for a higher status. Therefore, like ECMO and percutaneous support devices, the revised proposal includes strict criteria to qualify using this justification for status 2, and also adopts the stricter extension criteria described above.

Status 3

- Status 3: Dischargeable LVAD for 30 Days

Current policy permits stable candidates supported by a VAD to be registered as status 1A for 30 days at the transplant program’s discretion. The Committee discussed whether the 30 day optional period should continue as a policy at all.¹¹ Those who oppose the discretionary 30 day time cite studies that show that stable LVAD patients are at a much lower risk of experiencing adverse events while waiting for transplant, and are therefore not nearly as urgent as other candidates in status 3.^{12,13} Those who supported the

¹⁰ Based on OPTN data presented on October 22, 2015.

¹¹ D. M. Meyer; J. G. Rogers; L. B. Edwards; E. R. Callahan; S. A. Webber; M. R. Johnson; J. D. Vega; M. J. Zucker; J. C. Cleveland Jr., The Future Direction of the Adult Heart Allocation System in the United States. *American Journal of Transplantation*. 2015;15(1):44-54.

¹² Dardas T, Mokadam NA, Paqani F, Aaronson K, Levv WC. Transplant registrants with implanted left ventricular assist devices have insufficient risk to justify elective Organ Procurement and Transplantation Network status 1A time. *J Am Coll Cardiol* 2012; 60: 36–43.

¹³ Pinney SP. Timing isn’t everything: Donor heart allocation in the present LVAD era. *J Am Coll Cardiol* 2012; 60: 52–53.

optional 30 day period believe the TSAM analysis reveals that the candidates using the LVAD for 30 days discretionary time have lower waiting list mortality rates than others in status 3 as a direct result of an intentional compromise that provides candidates with a priority for a limited time without forcing them to risk developing a device complication in order to move up in urgency.

During public comment, the Committee received mixed feedback regarding whether to perpetuate the 30 day optional period, and the Committee itself remained divided. The Committee decided to include a question about whether to retain the 30 day discretionary period in the survey. Though the survey results were also nearly evenly split, more respondents (55%) were in favor of keeping the provision than not.

Ultimately, the Committee determined that the discretionary LVAD for 30 days policy should continue. It is an acceptable compromise that provides candidates supported by an LVAD with an opportunity for transplant while stable, which likely increases the opportunity for successful transplantation prior to the development of a device-related complication.

- **Status 3: Multiple Inotropes or a Single High Dose Inotrope and Hemodynamic Monitoring**
This status was largely informed by the requirements in current policy. To avoid inadvertently creating an incentive to administer inotropes in order to register a candidate as status 3, the Committee adopted the similar cardiogenic shock requirements for the initial qualifying period as ECMO, percutaneous devices, and IABP. In addition to the extension criteria designed for ECMO, IABP and percutaneous devices, the Committee proposes an alternative means for extending a candidate in this status through proof the candidate failed an attempt to be weaned off of inotropic support. The Committee proposes permitting transplant programs to provide evidence to the RRB that the candidate cannot be weaned from their inotropes through an $\text{SvO}_2 < 50\%$ measured by central venous catheter, because not all candidates supported by inotropes will have an invasive catheter.

Status 4

- **Status 4: Inotropes without Hemodynamic Monitoring**
The Committee proposes slight revisions to this criterion as compared to the original public comment proposal. The Committee was concerned that the cardiogenic shock requirements applicable to candidates that qualify for the multiple inotropes criterion in status 3 were too strict for those candidates in status 4 that are not necessarily admitted to the hospital. Therefore, to further distinguish candidates that qualify for the status 4 inotropes criterion from the status 3 inotropes criterion, the Committee proposes removing the blood pressure evidence from the cardiogenic shock requirement. Therefore, candidates that qualify for status 4 under this criterion would be treated with at least one inotrope for cardiogenic shock, as evidenced by a cardiac index of less than 2.2 L/min/m^2 , and a pulmonary capillary wedge pressure of greater than 15 mmHg.

- **Status 4: Congenital Heart Disease and Amyloidosis, Hypertrophic Cardiomyopathy (HCM), or Restrictive Cardiomyopathy (RCM)**
During public comment, the Committee received feedback that the specific diagnostic criteria in status 4 were appropriate for some candidates, but that some candidates with these diagnoses face unique challenges. Some suggested that the Committee create specific policy exceptions for these candidates to accommodate situations in which their conditions worsen quickly. The Committee determined that the variability in outcomes within these categories precludes strict definitions of appropriate exceptions in policy. Especially for patients with congenital heart disease, but also for others in this category, the current exception process remains the most appropriate way to attempt to stratify patients into appropriate statuses based on perceived risk of waitlist mortality. Additionally, the Committee believes that the exception process will be improved because RRBs will review cases from other regions, rather than their own, which may eliminate any perception of unfairness that exists with the current RRB case review process.

Status 5

- **Status 5: Combined Organ Transplants**
This status is reserved for heart transplant candidates that are registered on the waiting list at the same transplant hospital for another organ. If a heart candidate also requires another organ, and qualifies for a more urgent status, the candidate should be registered at that status instead. This criterion is intended to capture those candidates that do not otherwise qualify for a more urgent heart status but are registered for a second organ.

During public comment some confusion arose about the intent of this criterion. This criterion and this revised policy do not change multi-organ allocation policy, nor the way in which multi-organ allocation will

occur. Multi-organ allocation is an issue that will be addressed by a broader community of OPTN members in the future.

Additional Policy Clarifications

- Policy for Sensitized Candidates

On multiple occasions, the Committee discussed how to identify and prioritize sensitized patients. Though the Committee discussed multiple solutions, including review board exceptions or prioritization for candidates with a Calculated Panel Reactive Antibody (CPRA) of 80 percent and with three positive prospective crossmatches, the problem remains that this is not currently a required data field for transplant programs to complete, so the OPTN does not collect sufficient data on heart patients to strongly support any of these solutions. The Committee therefore proposes collecting CPRA data for candidates at intervals described in the “Will this proposal require members to submit additional data?” section below.

In the meantime, the Committee previously proposed a minor clarification to Policy 6.3.B: Exceptions to Allocation for Sensitized Patients. Current policy permits an OPO to allocate a heart out of sequence within a DSA to a sensitized candidate if the OPO and all transplant programs within the DSA agree. The proposed policy also permits this, but adds a restriction that the heart may be allocated out of sequence within the DSA but only within a status. The Committee believes this restriction is necessary because with broader sharing, an out-of-sequence allocation within a DSA would have a larger impact on candidates in Zone A than it would in the current system.

Because this policy may have a larger impact on candidates outside the DSA, the Committee also considered other options for modifying this policy. One option is to further modify the current policy to permit a sensitized candidate within the DSA to be prioritized for offers, but only to the extent that the candidate would not receive offers ahead of a candidate in Zone A that would otherwise be registered before the candidate. This option recognizes that even though transplant programs and the OPO in the DSA may agree to prioritize a candidate, all transplant programs in Zone A would not have the opportunity to do so and it would not be fair to prioritize a local candidate ahead of the Zone A candidate. Another option is to delete the policy altogether, and to require transplant programs to request exceptions from the RRB if the candidate is highly sensitized.

The Committee seeks the public’s feedback on this particular policy issue.

- RRB Policy

The Committee proposes clarifications to Policy 6.3.A: RRB and Committee Review of Status Exceptions, to streamline the RRB appeals process. The impetus for this proposed change is that candidates registered in the highest urgency statuses are expected to receive offers more quickly under the proposed adult heart allocation policy changes, so the review process for exceptions to be registered in these high urgency statuses should be explicitly clear.

The Committee considered whether exception requests should be decided by RRBs prospectively instead of retrospectively. A prospective review would ensure that candidates are not transplanted at a status that is not approved upon peer review by the RRB. However, prospective reviews are less favorable to the candidate, as the candidate is not permitted to be listed in the requested status until the RRB approves the request, which may take days. Conversely, retrospective reviews permit the candidate to wait in the requested status immediately, but the transplant program runs a risk that the candidate’s assignment to that status will not ultimately be approved by the RRB. Due to the logistical challenges of obtaining RRB approval prospectively in a timely manner, the Committee ultimately decided to continue to permit exception requests to be reviewed retrospectively.

Retrospective reviews present the possibility that a candidate will be transplanted before the RRB can review the request, and, if the RRB does not ultimately approve the request, the candidate would have been transplanted while in a status that reviewers do not agree was warranted. To ensure that transplant programs do not try to take advantage of this possibility, the Committee proposes giving the Thoracic Committee clear authority to review cases in which a candidate is transplanted at an unapproved status, and to determine whether the transplant program at which the candidate was registered should be referred to the Membership and Professional Standards Committee (MPSC) for further review. It is not a policy violation in and of itself to transplant a candidate before the exception request is granted, but the new policy does require transplant programs to pursue the request even if the candidate is transplanted to ensure that ultimately, the RRB or the Thoracic Committee approves of the candidate's registration in the requested status.

- Heart-Lung Allocation Policy

The Committee proposes additional policy clarifications that are necessary due to the change in status criteria and definitions. First, the Committee proposes changes to Policy 6.5.F: Allocation of Heart Lungs, to clarify that when allocating a heart-lung block from the lung or heart-lung match run, the OPO does not need to first offer the heart to all eligible heart-alone candidates in all zones. Instead, if the OPO generates a lung or heart-lung match, the OPO can offer the heart-lung to the heart-lung candidate after offering the heart to all eligible status 1 or status 2 candidates within the DSA and Zone A. The Committee proposes equating proposed status 1 and status 2 candidates to current status 1A candidates for the purposes of this section of policy. This clarification closely mirrors the guidance the Committee previously developed.¹⁴

How well does this proposal address the problem statement?

The Committee requested two TSAM analyses as it developed this proposal in order to simulate the impact of the proposed changes. The first simulation analysis demonstrated the projected impact of stratifying candidates based on a 6-tiered urgency system, rather than the current three tiers. The allocation rules for the first analysis were otherwise intended to mimic current allocation policy as closely as possible, so the first analysis does not include allocation which shares donated organs more broadly than the current allocation system. The second analysis was based on the proposed 6 urgency statuses, but also incorporated broader sharing schemes into the allocation rules.

For each analysis, the SRTR performed ten runs of the TSAM using a cohort of candidates and donors drawn from real data between 2009 and 2011. Each simulation run uses the same list of historically-derived donors and candidates from the cohort, but changes the order in which the donors appear, thus changing the order of candidates to whom offers are made. The simulations are run ten times with these different orderings to account for a range of variability. Thus, simulation results show a range of outcomes across the ten runs, as well as a point estimate of the average across the ten runs (ranges do not indicate confidence limits). The first TSAM analysis, which tested the projected impact of the 6-tiered urgency system with the current geographic sharing rules, showed reductions in overall waiting list mortality rates, increases in transplant rates among the most urgent patients, and similar post-transplant mortality overall as compared to the current system.¹⁵ Results of the first analysis are included in the figures in this proposal as "6 StatGrps" and will be referenced throughout this section as "6 urgency statuses."

The second TSAM analysis used the same cohort and builds on the results of the first analysis of the 6 urgency statuses. (**Exhibit A**) The Committee requested the SRTR model four different broader sharing

¹⁴ "Guidance to Organ Procurement Organizations for Allocation of Heart-Lung Blocks."

https://optn.transplant.hrsa.gov/media/1139/heart_lung_allocation_guidance.pdf (last visited January 15, 2016)

¹⁵ Colvin M, Pyke J, Skeans M, Wang X, Zeglin J. Final Analysis: Data Request from the Heart Subcommittee of the Thoracic Organ Transplantation Committee. Data Request ID: HR2014_05. March 23, 2015.

schemes, and the results are included in the second analysis report.¹⁶ The Committee ultimately decided to design the proposal based on the results shown for the modeling scheme shown in **Figure 5** below (Column: Location in Original Proposal). The original proposed scheme is demonstrated in the following figures as “6 GrpShare” and will be referenced throughout this section as “6 urgency statuses with broader sharing.”¹⁷

Figure 5: 6 Urgency Statuses Plus Broader Sharing; Original Proposal

New candidate status	Location in Original Proposal	New candidate status	Location in Revised Proposal
Status 1 adult + Status 1A pediatric	DSA + Zone A	Status 1 adult + Status 1A pediatric	DSA + Zone A
Status 1 adult + Status 1A pediatric	Zone B	Status 2 adult	DSA + Zone A
Status 2 adult	DSA + Zone A	Status 3 adult + Status 1B pediatric	DSA
Status 2 adult	Zone B	Status 1 adult + Status 1A pediatric	Zone B
Status 3 adult + Status 1B pediatric	DSA	Status 2 adult	Zone B
Status 4 adult	DSA	Status 4 adult	DSA
Status 3 adult + Status 1B pediatric	Zone A	Status 3 adult + Status 1B pediatric	Zone A
Status 3 adult + Status 1B pediatric	Zone B	Status 3 adult + Status 1B pediatric	Zone B
Status 5 adult + Status 2 pediatric	DSA	Status 5 adult + Status 2 pediatric	DSA
Status 6 adult + Status 2 pediatric	DSA	Status 6 adult + Status 2 pediatric	DSA
Status 1 adult + Status 1A pediatric	Zone C	Status 1 adult + Status 1A pediatric	Zone C
Status 2 adult	Zone C	Status 2 adult	Zone C
Status 3 adult + Status 1B pediatric	Zone C	Status 3 adult + Status 1B pediatric	Zone C
Status 4 adult	Zone A	Status 4 adult	Zone A
Status 5 adult	Zone A	Status 5 adult	Zone A
Status 6 adult + Status 2 pediatric	Zone A	Status 6 adult + Status 2 pediatric	Zone A
Status 1 adult + Status 1A pediatric	Zone D	Status 1 adult + Status 1A pediatric	Zone D
Status 2 adult	Zone D	Status 2 adult	Zone D
Status 3 adult + Status 1B pediatric	Zone D	Status 3 adult + Status 1B pediatric	Zone D
Status 4 adult	Zone B	Status 4 adult	Zone B
Status 5 adult	Zone B	Status 5 adult	Zone B
Status 6 adult + Status 2 pediatric	Zone B	Status 6 adult + Status 2 pediatric	Zone B
Status 1 adult + Status 1A pediatric	Zone E	Status 1 adult + Status 1A pediatric	Zone E
Status 2 adult	Zone E	Status 2 adult	Zone E

¹⁶ Colvin M, Bolch C, Pyke J, Skeans M, Wang X, Zeglin J. Analysis Report: Data Request from the Heart Subcommittee of the OPTN Thoracic Organ Transplantation Committee. Data Request ID: HR2015_01. October 26, 2015.


¹⁷ The data displayed in these figures as under the heading of “6 GrpShare” corresponds with the “Sh 1/2A” data in the second TSAM report.

Status 3 adult + Status 1B pediatric	Zone E	Status 3 adult + Status 1B pediatric	Zone E
Status 4 adult	Zone C	Status 4 adult	Zone C
Status 5 adult	Zone C	Status 5 adult	Zone C
Status 6 adult + Status 2 pediatric	Zone C	Status 6 adult + Status 2 pediatric	Zone C
Status 4 adult	Zone D	Status 4 adult	Zone D
Status 5 adult	Zone D	Status 5 adult	Zone D
Status 6 adult + Status 2 pediatric	Zone D	Status 6 adult + Status 2 pediatric	Zone D
Status 4 adult	Zone E	Status 4 adult	Zone E
Status 5 adult	Zone E	Status 5 adult	Zone E
Status 6 adult + Status 2 pediatric	Zone E	Status 6 adult + Status 2 pediatric	Zone E

As described in the “**How was this proposal developed?**” section above, the Committee now proposes a revised version of 6 urgency statuses with broader sharing. The primary change is the limitation of the initial broader geographic sharing to status 1 and 2 candidates within the donor’s DSA or Zone A. Status 1 and 2 candidates in Zone B are now classified after status 3 patients within the donor’s DSA (**Figure 5**: Column: Location in Revised Proposal).

The second TSAM analysis examining the use of the 6 urgency statuses with broader sharing rules indicated that waiting list mortality rates appeared to decrease under the broader sharing rules as compared to current rules or rules incorporating new statuses but without broader sharing. (**Figure 6**) The overall waiting list mortality rates in the proposed system are likely to decrease because organs will be allocated to sicker patients more quickly, removing these candidates from the pool of those at risk for dying while waiting. Candidates that are less urgent might not be transplanted as quickly, but they are also less likely to die while waiting.

Figure 6: Overall Waitlist Mortality Rates by Simulation




Waiting list mortality rates under the 6 urgency statuses and 6 urgency statuses with broader sharing appear to increase for patients at the highest urgency statuses compared to current rules (status 1 or 2, **Figure 7**). However, this change predominantly reflects the shorter waiting time for candidates at these statuses under the modeled changes, rather than an increase in the incidence of mortality. Specifically, the actual occurrence of death in the model ranges between 4 and 9 status 1 candidates with broader

sharing, compared to 11 to 19 deaths under current rules and 7 to 18 deaths with six urgency statuses without broader sharing. Thus, while the rate estimate is higher in the proposed system, the number of status 1 and 2 candidates predicted to die while waiting is lower than the current system. The rate increases because patients are either dying or being transplanted rapidly at these urgencies, so the time on the waiting list (the denominator) is decreasing.

The waiting list mortality rates for candidates registered as inactive also decrease in the proposed system, because more urgent candidates are projected to be transplanted before reaching a state in which they are too ill for transplant and transferring to “inactive” status. (**Figure 7**). This reduces the number of waiting list deaths and decreases overall waiting list mortality rates.


Figure 7: Waitlist Mortality Rates by Simulation and New Status Groups, Adult Candidates



To combat the high waiting list mortality for the most urgent patients, the Committee determined that it should allow these candidates access to a broader geographic range of donors. Because of this, the waiting list mortality rates for statuses 1, 2, and 3 noticeably decrease in the 6 urgency statuses with broader sharing scheme compared to the 6 urgency statuses. Though status 1 candidates exhibit the highest projected waiting list mortality rates, the rates are comparable to the rates in the current system, and the absolute number of deaths while waiting is notably lower. Additionally, the waiting list mortality rate for status 3 declines in the 6 urgency statuses with broader sharing scheme, which affects a much larger group of patients than those that would qualify for proposed statuses 1 and 2.


Overall transplant rates by simulation appeared to be slightly lower in the proposed sharing schemes than in the current rules. See **Figure 8**. However, the ranges of some sharing rules overlapped with the ranges exhibited in the current rules simulation. It is also important to remember that the bars in this graph represent the minimum and maximum results of the ten simulated runs; they are not the 95% confidence limits.

Figure 8: Overall Transplant Rates by Simulation



Importantly, the proposed system is intended to ensure that the most urgent candidates are transplanted more quickly, and the TSAM analysis of the proposed geographic sharing schemes demonstrate this goal. (**Figure 9**) Note that the upper y-axis limit is 9000 on the left panel and 120 on the right panel.


Figure 9: Transplant Rates by Simulation and New Status Groups, Adult Candidates



The Committee designed the proposed system to ensure that candidates most in need of transplant are prioritized in allocation. Broader sharing is projected to increase the transplant rates in status 1 and 2 because there are increased transplant counts and decreased waiting times for these patients, which contribute to higher rates. Under the current rules simulation, there are 51 transplants in status 1, but when applying broader sharing, the transplant counts increase nearly four-fold to 191. Status 1 transplant rates increase even more, from 615 transplants per 100 years on the waitlist under current rules, to 3,044 with six statuses, to 7,627 with six statuses plus broader sharing. The same pattern occurs in status 2. Increased transplant rates for these statuses under broader sharing are expected; the more priority given to statuses 1 and 2, the more one would expect to see the patients in these statuses receiving transplants. Transplant rates for status 3 candidates appear similar when comparing the current sharing rules to the proposed 6 urgency statuses with broader sharing. Status 4 candidates exhibit lower transplant rates for the two simulations involving the proposed statuses compared to the simulation based on current rules, but this was also expected. Importantly, there is not a marked increase in death counts, meaning the candidates wait longer, but are not dying more frequently.

In the proposed system, within each status the post-transplant mortality rates are projected to remain comparable to those rates in the current system. (Figure 10) One-year post-transplant mortality rates show a similar pattern.

Figure 10: Two-Year Post-Transplant Mortality Rates by Simulation and Tier, Adult Recipients



The post-transplant mortality rates for the simulations based on broader sharing trend slightly higher than the simulation based on current rules. The Committee expressed concern about unintentionally increasing post-transplant mortality rates as a result of increasing transplants in the most urgent patients. While status 1 post-transplant mortality rates appear to increase slightly, the modeling may not as accurately predict whether those candidates would do better if they were transplanted more quickly, as the post-transplant mortality models are based on outcomes in recipients transplanted under current rules, where all status 1A candidates receive the same priority. It is possible that these candidates may begin to have improved post-transplant mortality due to shorter wait times at the highest urgency. These are candidates that may have otherwise died while waiting for transplant.

The post-transplant death rates in status 1 are higher than in status 2, but are also based on a smaller death count. This result is expected because the number of transplants for status 1 candidates is likely to increase, and the modeling appears to show the post-transplant death rate rising in concert with the increased rate of transplants for candidates in the same status. The Committee agreed that though status 1 candidates may experience slightly higher post-transplant mortality rates, prioritizing them is a clinically acceptable compromise, particularly when delaying transplantation would likely result in death on the waiting list.

Based on the analyses described above, the Committee anticipates the proposed policies will decrease waiting list mortality rates by increasing transplant rates for the most urgent candidates by ensuring they are properly escalated to the most urgent status, and have access to the broadest range of donors. Such changes are not anticipated to negatively impact waiting list mortality rates for candidates in less urgent statuses. Additionally, while post-transplant mortality rates may increase slightly for the most urgent candidates, the Committee believes this is an appropriate risk in order to benefit the most the candidates most in need.

Which populations are impacted by this proposal?

All heart and heart-lung candidates will be impacted by this proposal. As of July 2, 2016, there are 4,088 heart candidates and 46 heart-lung candidates awaiting transplant.

This proposal mainly impacts adult heart candidates. The Committee does not anticipate this proposal will have a negative impact on pediatric candidates, and may even have a positive impact on pediatric access

to heart transplant. Though the number of pediatric candidates is small and therefore more difficult to analyze, the TSAM analysis shows total increased transplant counts for pediatric candidates under the 6 urgency status with broader sharing scheme, and the transplant rate for pediatric status 1A candidates increased. The overall death counts also decrease slightly. The Committee's proposed changes to the pediatric donor allocation sequence (to accommodate the new 6 adult statuses) are also expected to ensure that pediatric candidates are not negatively impacted by this proposal and may experience a slight benefit in terms of allocation.

How does this proposal impact the OPTN Strategic Plan?

1. *Increase the number of transplants:* There is no impact to this goal.
2. *Improve equity in access to transplants:* Revising the heart allocation system will provide more equitable access to transplants based on medical urgency and on geographic location. The proposal is primarily aligned with this strategic goal.
3. *Improve waitlisted patient, living donor, and transplant recipient outcomes:* Waiting list mortality rates for adult heart candidates are expected to improve under the proposed policy, as candidates most in need of transplant will be transplanted more quickly and therefore not dying while waiting for a transplant. Overall post-transplant mortality may increase slightly as more urgent candidates are transplanted at increased rates.
4. *Promote living donor and transplant recipient safety:* There is no impact to this goal.
5. *Promote the efficient management of the OPTN:* The proposed statuses may decrease the number of exception requests that are submitted to the regional review boards, because the new statuses incorporated into policy the conditions for many groups of candidates that previously applied for exceptions. Decreasing the number of exception requests will help the OPTN operate more efficiently by reducing staff time spent processing the requests, and reducing the amount of volunteer time required for regional review board members to review the requests.

How will the OPTN implement this proposal?

This proposal will require a significant level of effort to program the new status criteria and sharing schemes in UNetSM. Prior to implementation, the OPTN will provide transplant programs with a timeframe in which to update current candidates' information in UNet according to the new policy requirements. On the day of implementation, UNet will allocate organs using the new information. According to existing policy, within 24 hours of the implementation date, transplant programs should verify that their candidates' information is up-to-date in UNet, to ensure that their candidates are registered in the appropriate new urgency status. Candidates whose records are not updated by the time of implementation will appear in status 6 (or status 5 if the candidate is registered at the same transplant hospital for another organ).

Exceptions that are approved prior to implementation and exception requests that are in progress at the time of implementation will be ineffective upon implementation. Many of the exception requests are expected to be unnecessary upon implementation, because the proposed policy is intended to accommodate the conditions of many candidates who previously needed an exception.

The OPTN will ensure that waiting time accumulated under the old system will transition to the new system so that candidates already waiting will not be disadvantaged on the date of implementation. Waiting time will transfer and accumulate according to **Table 4**, below.

Table 4: Waiting Time Transfer and Accumulation

New Status	Waiting Time Calculated As
Status 1	Accumulated time at New Status 1 Plus accumulated time at Status 1A*
Status 2	Accumulated time at New Status 2 Plus accumulated time at New Status 1 Plus accumulated Time at Status 1A*
Status 3	Accumulated time at New Status 3 Plus accumulated time at New Status 2 Plus accumulated time at New Status 1 Plus accumulated time at Status 1A*
Status 4	Accumulated time at New Status 4 Plus accumulated time at New Status 3 Plus accumulated time at New Status 2 Plus accumulated time at New Status 1 Plus accumulated time at Status 1A* Plus accumulated time at Status 1B
Status 5	Accumulated time at New Status 5 Plus accumulated time at New Status 4 Plus accumulated time at New Status 3 Plus accumulated time at New Status 2 Plus accumulated time at New Status 1 Plus accumulated time at Status 1A* Plus accumulated time at Status 1B Plus accumulated Time at Old Status 2
Status 6	Accumulated time at New Status 6 Plus accumulated time at New Status 5 Plus accumulated time at New Status 4 Plus accumulated time at New Status 3 Plus accumulated time at New Status 2 Plus accumulated time at New Status 1 Plus accumulated time at Status 1A* Plus accumulated time at Status 1B Plus accumulated Time at Old Status 2 (same as total Waiting Time minus any Inactive Time)

*Accumulated time a status 1A includes any pre-January 1999 status 1 time.

The OPTN will educate members prior to implementation to ensure that all members know how to transition their patients to the new system.

How will members implement this proposal?

Transplant Hospitals

Members will need to update data for candidates registered on the waiting list prior to full implementation. Within 24 hours of implementation, members will need to verify their candidates' information is correct, and reflects the new requirements in the proposed policy to ensure that their candidate is registered at the most appropriate status. Members will also need to submit more data than is currently required for each candidate during each status change or update at intervals defined in the proposed policy.

Feedback received from some commenters during the original round of public comment suggested this change may impact transplant program costs, as some programs may need to hire more transplant surgeons to travel further to recover hearts from donors.

OPOs

The proposed policy includes changes to the allocation sequence to require hearts to be shared to the DSA and Zone A combined. Feedback received from some commenters during the original round of public comment suggested this change may impact OPO practices and costs, as broader sharing may increase the need for OPOs to travel by plane more frequently to recover hearts from donors. This impact may be mitigated by the current proposal, as the proposed allocation scheme shares hearts within the DSA and Zone A, as compared with the original sharing scheme which also shared to Zone B.

Histocompatibility Laboratories

Histocompatibility laboratories may perform more HLA testing for heart transplant candidates than current practice, as a candidate's CPRA is proposed to be collected at various intervals for all adult heart transplant candidates.

Will this proposal require members to submit additional data?

As explained above, the Committee considered creating a heart allocation score in lieu of proposing additional statuses, but could not do so due to the lack of necessary data in the OPTN data system. The Committee received feedback during the first round of public comment that some people would prefer the Committee develop a heart allocation score, or that they are supportive of the creation of a score in the future. The Committee learned lessons from its development of the lung allocation score (LAS) in the past, and recognizes that in order to effectively develop a score, the same data must be collected for all candidates at established intervals.

Presumably, like the LAS, the heart allocation score will weigh waiting list mortality risk against post-transplant survival risk. Therefore, the Committee identified various factors that published studies and clinical consensus find influence a candidate's risk of mortality on the waiting list or post-transplant mortality (**Appendix B**). The Committee recognizes the list in Appendix B may be over-inclusive, and therefore seeks public comment on whether it is exhaustive or whether any data elements should be deleted for lack of predictive power or lack of feasibility for collecting the information on all candidates. The Committee also seeks feedback on whether some data should be collected only on candidates supported by VADs.

Improved risk stratification and risk adjustment may also be achieved through enhanced data collection. The data currently reported to the OPTN do not provide adequate information to allow for more precise risk adjustment based on current practices. Risk influences transplant program behavior. Transplant programs that perceive a candidate as “high-risk” may be less likely to transplant the candidate to avoid a potentially poor post-transplant outcome. If risk adjustment is precise, transplant programs can make more informed decisions about the relative benefit or risk of transplanting a particular candidate. The SRTR may incorporate these new data into the risk adjustment models that inform the program specific reports.

Data that are currently collected on the Tiedi® forms will continue to be collected as it is currently performed. Additionally, the mechanical circulatory support device information that transplant programs report to the OPTN retrospectively when a candidate is removed from Waitlist will continue to be collected as it is currently.

The Committee proposes that data be collected for all candidates with the submission of every status justification form. For those statuses that in the original proposal did not have a time limit, the Committee proposes establishing a 90 day qualifying period, and to extend a candidate in those statuses the transplant program will submit the requested data every 90 days with the status justification form. The Committee requests feedback regarding the proposed frequency of data collection for candidates in those statuses.

How will members be evaluated for compliance with this proposal?

The proposed policy modifications will not affect the methods by which UNOS staff routinely review members, but the content of the review may change based on the proposed modifications.

UNOS staff will continue to review all deceased donor match runs that result in a transplanted organ to ensure that allocation was carried out according to OPTN requirements and will continue to investigate potential policy violations.

At transplant hospitals, site surveyors will continue to review a sample of medical records, and any material incorporated into the medical record by reference, for documentation that:

- Information reported on the adult status justification form is consistent with source documentation
- The candidate met the requirements for the qualifying criterion selected on the adult status justification form and any required sub-criteria
- The candidate's medical urgency status or qualifying criteria used to justify the status were updated in UNetSM within 24 hours of a change in the candidate's medical condition to accurately reflect the change in condition

How will the sponsoring Committee evaluate whether this proposal was successful post implementation?

The Thoracic Committee will review waiting list and transplant data for all ages to ensure that this change in allocation serves its intended purpose without negatively impacting pre- or post-transplant outcomes for pediatric candidates/recipients. Outcomes in other populations may be assessed for unintended consequences as warranted; stratifications that may be considered include gender and race.

Since external factors and other changes in transplant policy can have an influence on the period following policy implementation, interpreting the apparent impact of this policy change based on “before vs. after” analysis must be done with caution.

Questions that will need to be answered as policy evaluation:

The following questions, and any others subsequently requested by the Committees, will guide the evaluation of the proposal after implementation.

- Have death rates for adult candidates on the heart waiting list decreased?
- Have transplant rates for adult candidates on the heart waiting list increased?
- Have post-transplant survival rates for adult heart recipients changed?
- Has the zonal distribution of heart transplants changed?
- Has the number of exception requests decreased?
- Has the heart utilization rate increased?

Data used to evaluate the proposal (Policy Performance Measures):

The following metrics, and any others subsequently requested by the Committee, will be used to evaluate the proposal. These metrics will be provided for the post-policy period, and compared to the pre-policy period, where possible. For pre- and post-policy comparisons involving medical urgency status, an approximate correspondence will be used: current status 1A compared to proposed statuses 1-3, and current status 1B compared to proposed tiers 4 and 5.

- Waiting list additions stratified by:
 - Medical urgency status
 - Criteria within medical urgency status
 - Region
 - Medical urgency status within Region
- Waiting list death rates stratified by:
 - Medical urgency status
 - Criteria within medical urgency status
 - Region
 - Medical urgency status within Region
- Waiting list transplant rates stratified by:
 - Medical urgency status
 - Criteria within medical urgency status
 - Region
 - Medical urgency status within Region
- Transplants stratified by:
 - Medical urgency status
 - Criteria within medical urgency status
 - Region
 - Medical urgency status within Region
 - Zone (DSA, Zone A, Zone B, etc.)
- Post-transplant patient survival stratified by:
 - Medical urgency status
 - Criteria within medical urgency status
 - Region
 - Medical urgency status within Region
 - Zone (DSA, Zone A, Zone B, etc.)
- Exception requests stratified by:
 - Medical urgency status
 - Region
 - Medical urgency status within Region
- Utilization of deceased donor hearts stratified by:
 - Donor age
 - Region

Timeline for evaluation:

The initial data analysis will be performed after the policy has been in place for about 6 months. Data will be evaluated no more frequently than every 6 months for the first two years and annually thereafter until 5 years post-implementation. Timeline is subject to change based on the results.

Policy or Bylaws Language

Proposed new language is underlined (example) and language that is proposed for removal is struck through (~~example~~).

6.1 Adult Status Assignments and Update Requirements

Each adult heart transplant candidate at least 18 years old at the time of registration is assigned a status that reflects the candidate's medical urgency for transplant. The candidate's transplant program must submit a heart status justification form to the OPTN Contractor to assign a candidate the status for which the candidate qualifies. Transplant programs must assign candidates on the waiting list that are not currently suitable for transplant to the inactive status.

~~Heart candidates at least 18 years old at the time of registration may be assigned any of the following:~~

- ~~• Adult status 1A~~
- ~~• Adult status 1B~~
- ~~• Adult status 2~~
- ~~• Inactive status~~

~~Heart candidates less than 18 years old at the time of registration may be assigned any of the following:~~

- ~~• Pediatric status 1A~~
- ~~• Pediatric status 1B~~
- ~~• Pediatric status 2~~
- ~~• Inactive status~~

~~A candidate registered on the waiting list before turning 18 years old remains eligible for pediatric status until the candidate has been removed from the waiting list.~~

If a candidate's medical condition changes and the criteria used to justify that candidate's status is no longer accurate, then the candidate's transplant program must submit a new heart status justification form to the OPTN Contractor within 24 hours of the change in medical condition.

If a candidate's transplant program does not submit a heart status justification form or the status expires and the transplant program does not submit a new heart status justification form, the candidate is assigned to status 6, or status 5 if the candidate is registered for another organ.

Transplant programs must report to the OPTN Contractor for each candidate all the following applicable data each time the transplant program submits a status justification form:

- Hemodynamic assessment results
- Functional status or exercise testing results
- Heart failure severity or end organ function indicators
- Heart failure therapies
- Mechanical support
- Sensitization risk, including CPRA, peak PRA, and number of prior sternotomies
- Current diagnosis

6.1.A **Adult Heart Status 1A Requirements**

To assign a candidate to adult status 1A, the candidate's transplant program must submit a *Heart Status 1A Justification Form* to the OPTN Contractor. A candidate is not assigned to adult status 1A until this form is submitted.

46 If the candidate is at least 18 years old at the time of registration then the candidate's transplant
47 program may assign the candidate to adult status 1A if the candidate has at least one either of
48 the following conditions ~~is met~~:

- 49
- 50 • Is supported by veno-arterial extracorporeal membrane oxygenation (VA ECMO), according
51 to Policy 6.1.A.i below.
- 52 • Is supported by a surgically implanted, non-endovascular biventricular support device
53 according to Policy 6.1.A.ii below.
- 54 • Is supported by a mechanical circulatory support device (MCSD) and has a life-threatening
55 ventricular arrhythmia according to 6.1.A.iii below.

56 **6.1.A.i Veno-Arterial Extracorporeal Membrane Oxygenation** 57 **(VA ECMO)**

58 A candidate's transplant program may assign a candidate to adult status 1 if the
59 candidate is admitted to the transplant hospital that registered the candidate on the
60 waiting list, and is supported by VA ECMO for cardiogenic shock as evidenced by
61 either of the following:

- 62 1. Within 7 days prior to VA ECMO support, all of the following are true:
 - 63 a. Systolic blood pressure <90 mmHg
 - 64 b. Cardiac index <1.8 L/min/m² if the candidate is not supported by inotropes or
65 <2.0 L/min/m² if the candidate is supported by at least one inotrope
 - 66 c. Pulmonary capillary wedge pressure >15 mmHg
- 67 2. If hemodynamic measurements could not be obtained within 7 days prior to VA
68 ECMO support, at least one of the following is true within 24 hours prior to VA
69 ECMO support:
 - 70 a. CPR was performed on the candidate
 - 71 b. Systolic blood pressure <70 mmHg
 - 72 c. Arterial lactate >4 mmol/L
 - 73 d. Aspartate transaminase (AST) or alanine transaminase (ALT) > 1,000 U/L

74 Candidates that meet either of the criteria above will remain in this status for up to 14
75 days from submission of the Heart Status 1 Justification Form. After 14 days, the
76 transplant program may apply to the regional review board (RRB) to extend the
77 candidate at this status if the candidate remains supported by VA ECMO. The
78 transplant program must provide to the RRB objective evidence of both of the
79 following:

- 80 1. The candidate demonstrated a contraindication to being supported by a durable
81 device
- 82 2. The transplant program failed at weaning the candidate from VA ECMO as
83 evidenced by at least one of the following:
 - 84 • Mean arterial pressure (MAP) < 60 mmHg
 - 85 • Cardiac index <2.0 L/min/ m²
 - 86 • Pulmonary capillary wedge pressure >15
 - 87 • SvO₂ <50% measured by central venous catheter

88

89 The RRB will retrospectively review extension requests. If the candidate is still
90 supported by VA ECMO after 14 days and either the extension request is not granted
91 or the transplant program does not request an extension, then the transplant program
92 may assign the candidate to status 3.

93

94 **6.1.A.ii Surgically Implanted, Non-Endovascular Biventricular**
 95 **Support Device**

96 A candidate's transplant program may assign a candidate to adult status 1 if the
 97 candidate is admitted to the transplant hospital that registered the candidate on the
 98 waiting list and is supported by a surgically implanted, non-endovascular biventricular
 99 support device and must remain hospitalized because the device is not FDA-
 100 approved for out of hospital use.

101 This status is valid for up to 14 days from submission of the Heart Status 1
 102 Justification Form. This status can be extended by the transplant program every 14
 103 days by submission of another Heart Status 1 Justification Form.

104 **6.1.A.iii Mechanical Circulatory Support Device (MCSD) with Life**
 105 **Threatening Ventricular Arrhythmia**

106
 107 A candidate's transplant program may assign a candidate to adult status 1 if the
 108 candidate is admitted to the transplant hospital that registered the candidate on the
 109 waiting list, is supported by an MCSD, and is experiencing recurrent or sustained
 110 ventricular tachycardia or ventricular fibrillation as evidenced by at least one of the
 111 following:

- 112 • Placement of a biventricular mechanical circulatory support device for the
 113 treatment of sustained ventricular arrhythmias
- 114 • That the patient was not considered a candidate for other treatment alternatives
 115 by an electrophysiologist, such as ablation, and has experienced three or more
 116 episodes of ventricular fibrillation or ventricular tachycardia separated by at least
 117 an hour, over the previous 14 days that both:
 - 118 1. Occurred in the setting of normal serum magnesium and potassium levels
 - 119 2. Required electrical cardioversion in a candidate receiving antiarrhythmic
 120 therapies

121
 122 This status is valid for up to 14 days from submission of the Heart Status 1
 123 Justification Form. This status can be extended by the transplant program every 14
 124 days by submission of another Heart Status 1 Justification Form if the candidate
 125 remains hospitalized on intravenous anti-arrhythmic therapy.

- 126 1. ~~The candidate is admitted to the transplant hospital that registered the candidate on the~~
 127 ~~waiting list, or an affiliated Veteran's Administration (VA) hospital, and the candidate also~~
 128 ~~meets at least one of the requirements in Table 6-1 below.~~
 129

130 **Table 6-1: Adult Status 1A Requirements for Candidates Currently Admitted to the Transplant**
 131 **Hospital**

If the candidate meets this condition:	Then adult status 1A is valid for:
<p>Has one of the following mechanical circulatory support devices in place:</p> <ul style="list-style-type: none"> • Total artificial heart (TAH) • Intra-aortic balloon pump • Extracorporeal membrane oxygenation (ECMO) 	<p>14 days, and must be recertified by an attending physician every 14 days from the date of the candidate's initial registration as adult status 1A to extend the adult status 1A registration.</p>

If the candidate meets this condition:	Then adult status 1A is valid for:
Requires continuous mechanical ventilation	14 days, and must be recertified by an attending physician every 14 days from the date of the candidate's initial registration as adult status 1A to extend the Status 1A registration.
Requires continuous infusion of a single high-dose intravenous inotrope or multiple intravenous inotropes, and requires continuous hemodynamic monitoring of left ventricular filling pressures. The OPTN Contractor will maintain a list of the OPTN-approved qualifying inotropes and doses.	7 days, and may be renewed for additional 7 day periods for each occurrence of an adult status 1A listing under this criterion for this candidate.

132
133
134
135
136
137

2. ~~A candidate who is at least 18 years old at the time of registration, and may or may not be currently admitted to the transplant hospital, may be assigned adult status 1A if the candidate meets at least one of the requirements in Table 6-2 below.~~

Table 6-2: Adult Status 1A Requirements for Candidates- Current Hospitalization Not Required

If the candidate meets this condition:	Then the status is valid for:
Has one of the following mechanical circulatory support devices in place: <ul style="list-style-type: none"> • Left ventricular assist device (LVAD) • Right ventricular assist device (RVAD) • Left and right ventricular assist devices (BiVAD) 	30 days, and the candidate may be registered as adult status 1A for 30 days at any point after being implanted once an attending physician determines the candidate is medically stable. The 30 days do not have to be consecutive. However, if the candidate undergoes a procedure to receive another device, then the candidate qualifies for a new term of 30 days. Any 30 days granted by the new device would substitute and not supplement any time remaining from the previous adult status 1A classification.
Candidate has mechanical circulatory support and there is medical evidence of significant device-related complications including, but not limited to, thromboembolism, device infection, mechanical failure, or life-threatening ventricular arrhythmias. A candidate's sensitization is not an acceptable device-related complication to qualify as adult status 1A. If a transplant program reports a complication that is not listed here, the registration will be retrospectively reviewed by the heart regional review board (RRB)	14 days, and must be recertified by an attending physician every 14 days from the date of the candidate's initial registration as adult status 1A to extend the adult status 1A registration.

138
139
140
141
142

~~If the attending physician does not update the qualifications for adult status 1A registration when required according to Tables 6-1 and 6-2 above, then the candidate's adult status 1A will expire and the candidate will be downgraded to adult status 1B.~~

6.1.B Adult Heart Status 2 Status 1B Requirements

To assign a candidate to adult status 2 ~~status 1B~~, the candidate's transplant program must submit a Heart Status 2 Status 1B Justification Form to the OPTN Contractor. A candidate is not assigned adult status 2 ~~status 1B~~ until this form is submitted.

~~The candidate's transplant program may assign the candidate as adult status 1B i~~ If the candidate is at least 18 years old at the time of registration then the candidate's transplant program may assign the candidate to adult status 2 if and the candidate has at least *one* of the following devices or therapies in place conditions:

- Is supported by a surgically implanted, non-endovascular left ventricular assist device (LVAD), according to Policy 6.1.B.i below.
- Is supported by a total artificial heart (TAH), biventricular assist device (BiVAD), right ventricular assist device (RVAD), or ventricular assist device (VAD) for single ventricle patients, according to Policy 6.1.B.ii below.
- Is supported by a mechanical circulatory support device (MCS) that is malfunctioning, according to Policy 6.1.B.iii below.
- Is supported by a percutaneous endovascular circulatory support device, according to Policy 6.1.B.iv below.
- Is supported by an intra-aortic balloon pump (IABP), according to Policy 6.1.B.v below.
- Is experiencing recurrent or sustained ventricular tachycardia or ventricular fibrillation according to Policy 6.1.B.vi below.

6.1.B.i Surgically Implanted, Non-Endovascular Left Ventricular Assist Device (LVAD)

A candidate's transplant program may assign a candidate to adult status 2 if the candidate is admitted to the transplant hospital that registered the candidate on the waiting list and is supported by a surgically implanted, non-endovascular LVAD and must remain hospitalized because the device is not FDA-approved for out of hospital use.

Candidates that meet the criteria above will remain in this status for 14 days. After 14 days, the transplant program may apply to the RRB to extend the candidate's registration if the candidate remains supported by the surgically implanted, non-endovascular LVAD. The transplant program must provide to the RRB objective evidence of both of the following:

1. The candidate demonstrated a contraindication to being supported by a durable device
2. The transplant program failed at weaning the candidate from the surgically implanted, non-endovascular LVAD as evidenced by:
 - Mean arterial pressure (MAP) <60 mmHg
 - Cardiac index <2.0 L/min/ m²
 - Pulmonary capillary wedge pressure >15
 - SvO₂ <50% measured by central venous catheter

The RRB will retrospectively review extension requests. If the candidate is still supported by the surgically implanted, non-endovascular LVAD after 14 days and either the extension request is not granted or the transplant program does not request an extension, then the transplant program may assign the candidate to status 3.

192 **6.1.B.ii Total Artificial Heart (TAH), BiVAD, Right Ventricular**
193 **Assist Device (RVAD), or Dischargeable Ventricular**
194 **Assist Device (VAD) for Single Ventricle Patients**

195 A candidate's transplant program may assign a candidate to adult status 2 if the
196 candidate is supported by *any* of the following:

- 197 • A TAH
- 198 • An RVAD alone
- 199 • A BiVAD
- 200 • A VAD, for single ventricle patients only

201
202 This status is valid for up to 14 days from submission of *the Heart Status 2*
203 *Justification Form*. This status can be extended by the transplant program every 14
204 days by submission of another *Heart Status 2 Justification Form*.

205 **6.1.B.iii Mechanical Circulatory Support Device (MCSD) with**
206 **Malfunction**

207 A candidate's transplant program may assign a candidate to adult status 2 if the
208 candidate is admitted to the transplant hospital that registered the candidate on the
209 waiting list and is supported by an MCSD that is experiencing device malfunction as
210 evidenced by *all* of the following:

- 211 1. Malfunction of at least one of the components of the MCSD
- 212 2. Malfunction cannot be fixed without an entire device replacement
- 213 3. Malfunction that is currently causing inadequate circulatory support or places the
214 candidate at imminent risk of device stoppage

215
216 This status is valid for up to 14 days from submission of *the Heart Status 2*
217 *Justification Form*. This status can be extended by the transplant program every 14
218 days by submission of another *Heart Status 2 Justification Form*.

219
220 **6.1.B.iv Percutaneous Endovascular Mechanical Circulatory**
221 **Support Device**

222
223 A candidate's transplant program may assign a candidate to adult status 2 if the
224 candidate is admitted to the transplant hospital that registered the candidate on the
225 waiting list, and is supported by a percutaneous endovascular mechanical circulatory
226 support device without an oxygenator for cardiogenic shock as evidenced by *either* of
227 the following:

- 228 1. Within 7 days prior to percutaneous endovascular mechanical circulatory
229 support, *all* of the following are true:
 - 230 a. Systolic blood pressure <90 mmHg
 - 231 b. Cardiac index <1.8 L/min/m² if the candidate is not supported by inotropes or
232 <2.0 L/min/m² if the candidate is supported by inotropes
 - 233 c. Pulmonary capillary wedge pressure >15 mmHg
- 234 2. If hemodynamic measurements could not be obtained within 7 days prior to
235 percutaneous endovascular mechanical support, *at least one* of the following is
236 true within 24 hours prior to percutaneous endovascular mechanical circulatory
237 support:
 - 238 • CPR was performed on the candidate
 - 239 • Systolic blood pressure <70 mmHg
 - 240 • Arterial lactate >4 mmol/L
 - 241 • Aspartate transaminase (AST) or alanine transaminase (ALT) > 1,000 U/L

243 Candidates that meet the criteria above will remain in this status for 14 days. After 14
244 days, the transplant program may apply to the RRB to extend the candidate's status if the
245 candidate remains supported by the percutaneous endovascular circulatory support
246 device. The transplant program must provide to the RRB objective evidence of both of
247 the following:

- 248 1. The candidate demonstrated a contraindication to being supported by a durable
249 device
- 250 2. The transplant program failed at weaning the candidate from the acute
251 percutaneous endovascular circulatory support device evidenced by:
 - 252 • Mean arterial pressure (MAP) <60 mmHg
 - 253 • Cardiac index <2.0 L/min/ m²
 - 254 • Pulmonary capillary wedge pressure >15
 - 255 • SvO₂ <50% measured by central venous catheter

256 The RRB will retrospectively review extension requests. If the candidate is still
257 supported by the percutaneous endovascular mechanical circulatory support device
258 after 14 days and either the extension request is not granted or the transplant
259 program does not request an extension, then the transplant program may assign the
260 candidate to status 3.

261 **6.1.B.v Intra-Aortic Balloon Pump (IABP)**

263 A candidate's transplant program may assign a candidate to adult status 2 if the
264 candidate is admitted to the transplant hospital that registered the candidate on the
265 waiting list, and is supported by an IABP for cardiogenic shock as evidenced by
266 either of the following:

- 267 1. Within 7 days prior to IABP support, all of the following are true:
 - 268 a. Systolic blood pressure <90 mmHg
 - 269 b. Cardiac index <1.8 L/min/m² if the candidate is not supported by inotropes or
270 <2.0 L/min/m² if the candidate is supported by inotropes
 - 271 c. Pulmonary capillary wedge pressure >15 mmHg
- 272 2. If hemodynamic measurements could not be obtained within 7 days prior to IABP
273 support, at least one of the following is true within 24 hours prior to IABP support:
 - 274 a. CPR was performed on the candidate
 - 275 b. Systolic blood pressure <70 mmHg
 - 276 c. Arterial lactate >4 mmol/L
 - 277 d. AST or ALT > 1,000 U/L

278
279 Candidates that meet the criteria above will remain in this status for 14 days. After 14
280 days, the transplant program may apply to the RRB to extend the candidate's status
281 if the candidate remains supported by the IABP. The transplant program must
282 provide to the RRB objective evidence of both of the following:

- 283 1. The candidate demonstrated a contraindication to being supported by a durable
284 device
- 285 2. The transplant program failed at weaning the candidate from the IABP as
286 evidenced by:
 - 287 • Mean arterial pressure (MAP) <60 mmHg
 - 288 • Cardiac index <2.0 L/min/ m²
 - 289 • Pulmonary capillary wedge pressure >15
 - 290 • SvO₂ <50% measured by central venous catheter

291 The RRB will retrospectively review extension requests. If the candidate is still
292 supported by the IABP after 14 days and either the extension request is not granted
293 or the transplant program does not request an extension, then the transplant program
294 may assign the candidate to status 3.

296 **6.1.B.vi Ventricular Tachycardia (VT) or Ventricular Fibrillation**
297 **(VF)**

298 A candidate's transplant program may assign a candidate to adult status 2 if the
299 candidate is admitted to the transplant hospital that registered the candidate on the
300 waiting list, is not considered a candidate for other treatment alternatives such as
301 ablation, and is experiencing recurrent or sustained VT or VF with at least three
302 episodes separated by at least one hour within a period of 14 days. The VT or VF
303 episodes must have *both*:

- 304
305 1. Occurred in the setting of normal serum magnesium and potassium levels
306 2. Required electrical cardioversion in a candidate receiving intravenous
307 antiarrhythmic therapies

308 This status is valid for up to 14 days from submission of the *Heart Status 2*
309 *Justification Form*. This status can be extended by the transplant program every 14
310 days by submission of another *Heart Status 2 Justification Form*.

- 311
312 1. ~~Left ventricular assist device (LVAD)~~
313 2. ~~Right ventricular assist device (RVAD)~~
314 3. ~~Left and right ventricular assist devices (BiVAD)~~
315 4. ~~Continuous infusion of intravenous inotropes~~

316 ~~Candidates that continue to qualify for adult status 1B may retain this status for an unlimited~~
317 ~~period and this status does not require any recertification, unless the candidate's medical~~
318 ~~condition changes as described in *Policy 6.2: Status Updates*.~~

320 **6.1.C Adult Heart Status 3 Status-2 Requirements**

321 ~~If the candidate is at least 18 years old at the time of registration and does not meet the criteria~~
322 ~~for adult status 1A or 1B but is suitable for transplant, then the candidate may be assigned adult~~
323 ~~status 2.~~

324
325 ~~The candidate may retain adult status 2 for an unlimited period and this status does not require~~
326 ~~recertification, unless the candidate's medical condition changes as described in *Policy 6.2:*~~
327 ~~*Status Updates*.~~

328 To assign a candidate to adult status 3, the candidate's transplant program must submit a *Heart*
329 *Status 3 Justification Form* to the OPTN Contractor. A candidate is not assigned adult status 3
330 until this form is submitted.

331
332 If the candidate is at least 18 years old at the time of registration then the candidate's transplant
333 program may assign the candidate adult status 3 if the candidate has at least *one* of the following
334 conditions:

- 335
336 • Is supported by a dischargeable left ventricular assist device and is exercising 30 days of
337 discretionary time, according to *Policy 6.1.C.i* below.
338 • Is supported by multiple inotropes or a single high dose inotrope and has hemodynamic
339 monitoring, according to *Policy 6.1.C.ii* below.
340 • Is supported by a mechanical circulatory support device (MCSD) with hemolysis, according to
341 *Policy 6.1.C.iii* below.
342 • Is supported by an MCSD with pump thrombosis, according to *Policy 6.1.C.iv* below.
343 • Is supported by an MCSD and has right heart failure, according to *Policy 6.1.C.v* below.
344 • Is supported by an MCSD and has a device infection, according to *Policy 6.1.C.vi* below.
345 • Is supported by an MCSD and has bleeding, according to *Policy 6.1.C.vii* below.
346 • Is supported by an MCSD and has aortic insufficiency, according to *Policy 6.1.C.viii* below.

- Is supported by veno-arterial extracorporeal membrane oxygenation (VA ECMO) after 14 days, according to Policy 6.1.C.ix below.
- Is supported by a percutaneous endovascular circulatory support device after 14 days, according to Policy 6.1.C.x below.
- Is supported by an intra-aortic balloon pump (IABP) after 14 days, according to Policy 6.1.C.xi below.

6.1.C.i Dischargeable Left Ventricular Assist Device (LVAD) for Discretionary 30 Days

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is supported by a dischargeable LVAD. The OPTN Contractor maintains a list of OPTN-approved, qualifying devices.

The candidate may be registered as status 3 for 30 days at any point after being implanted with the dischargeable LVAD and once the attending physician determines the candidate is medically stable. Regardless of whether the candidate has a single transplant program registration or multiple transplant program registrations, the candidate receives a total of 30 days discretionary time for each dischargeable LVAD implanted across all registrations. Each day used by any of the transplant programs counts towards the cumulative 30 days.

The 30 days do not have to be consecutive and if the candidate undergoes a procedure to receive another replacement dischargeable LVAD, then the candidate qualifies for a new term of 30 days. When a candidate receives a replacement device, the 30 day period begins again, and the candidate cannot use any time remaining from the previous period.

6.1.C.ii Multiple Inotropes or a Single High Dose Inotrope and Hemodynamic Monitoring

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is admitted to the hospital that registered the candidate on the waiting list, and within 7 days prior to inotrope administration or while on inotropes meets *all* of the following:

1. Has *one* of the following:
 - Invasive pulmonary artery catheter
 - Daily hemodynamic monitoring to measure cardiac output and left ventricular filling pressures
2. Is in cardiogenic shock, as evidenced by *all* of the following:
 - Systolic blood pressure <90 mmHg
 - Pulmonary Capillary Wedge Pressure >15 mmHg
 - Cardiac index of *either*:
 - <1.8 L/min/m² for candidates without inotropic or mechanical support within 7 days prior to inotrope administration
 - <2.2 L/min/m² for candidates with inotropic or mechanical support
3. Is supported by *one* of the following:
 - A continuous infusion of *at least one* high-dose intravenous inotrope
 - Dobutamine greater than or equal to 7.5 mcg/kg/min
 - Milrinone greater than or equal to 0.50 mcg/kg/min
 - Epinephrine greater than or equal to 0.02 mcg/kg/min
 - A continuous infusion of *at least two* multiple intravenous inotropes
 - Dobutamine greater than or equal to 3 mcg/kg/min
 - Milrinone greater than or equal to 0.25 mcg/kg/min
 - Epinephrine greater than or equal to 0.01 mcg/kg/min

400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450

- Dopamine greater than or equal to 3 mcg/kg/min

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form if the candidate remains admitted to the hospital that registered the candidate on the waiting list, and the candidate remains supported by ongoing use of the qualifying inotrope therapy and at least one of the following:

- Invasive pulmonary artery catheter or daily hemodynamic monitoring to measure cardiac output and left ventricular filling pressures
- Cardiac index less than 2.2 L/min/m² on the current medical regimen
- Failed attempt to wean the inotrope support documented by one of the following:
 - Cardiac index less than 2.2 L/min/m² during dose reduction
 - Increase in serum creatinine by 20% over the value immediately prior to, and within 24 hours of, inotrope dose reduction
 - Increase in arterial lactate to greater than 2.5 mmol/L
 - SvO₂ <50% measured by central venous catheter

6.1.C.iii Mechanical Circulatory Support Device (MCSD) with Hemolysis

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is supported by an MCSD and is not experiencing device malfunction, but is experiencing hemolysis, as evidenced by both of the following:

1. Two separate blood samples measured within 48 hours of each other confirming markers of active hemolysis as evidenced by at least two of the following criteria:
 - Lactate dehydrogenase (LDH) at least 2.5 times the upper limit of normal at the laboratory reference range
 - Plasma free hemoglobin greater than 20 mg/dL
 - Hemoglobinuria
2. Documentation of at least one attempt to treat the condition using an intravenous anticoagulant, intravenous anti-platelet agent, or thrombolytic, with persistent or recurrent hemolysis

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form.

6.1.C.iv Mechanical Circulatory Support Device (MCSD) with Pump Thrombosis

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is supported by an MCSD and is experiencing pump thrombosis as evidenced by at least one of the following:

- Visually detected thrombus in a paracorporeal ventricular assist device (VAD)
- Transient ischemic attack, stroke, or peripheral thromboembolic event, non-invasive testing to exclude intracardiac thrombus in all candidates, and significant carotid artery disease in candidates with a neurological event

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form.

451
452
453

6.1.C.v Mechanical Circulatory Support Device (MCSD) with Right Heart Failure

454
455
456
457
458

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is supported by an MCSD and has at least moderate right ventricular malfunction in the absence of left ventricular assist device (LVAD) malfunction, and all of the following:

459
460
461
462
463
464
465
466
467
468

1. Requires treatment with at least one of the following therapies for at least 14 days:
 - Dobutamine greater than or equal to 5 mcg/kg/min
 - Dopamine greater than or equal to 4 mcg/kg/min
 - Epinephrine greater than or equal to 0.05 mcg/kg/min
 - Inhaled nitric oxide
 - Intravenous prostacyclin
 - Milrinone greater than or equal to 0.35 mcg/kg/min
2. Has, within 7 days prior to initiation of any of the therapies above, pulmonary capillary wedge pressure < 20 mm Hg and central venous pressure > 18 mm Hg

469
470
471
472
473

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form.

474
475
476

6.1.C.vi Mechanical Circulatory Support Device (MCSD) with Device Infection

477
478
479
480
481
482

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is supported by an MCSD and is experiencing a pump-related local or systemic infection, with at least one of symptoms according to Table 6-1: Evidence of Device Infection below.

Table 6-1: Evidence of Device Infection

<u>If the candidate has evidence of:</u>	<u>Then this status is valid:</u>
<u>Erythema and pain along the driveline, with either leukocytosis or a 50 percent increase in white blood cell count from the last recorded white blood cell count, and either:</u> <ul style="list-style-type: none"> • <u>Positive bacterial or fungal cultures from the driveline exit site within the last 14 days</u> • <u>A culture-positive fluid collection between the exit site and the device</u> 	<u>For 14 days from submission of the Heart Status 3 Justification Form.</u>
<u>Debridement of the driveline with positive cultures from sites between the exit site and the device</u>	<u>For 14 days from submission of the Heart Status 3 Justification Form.</u>
<u>Bacteremia treated with antibiotics</u>	<u>For 42 days from submission of the Heart Status 3 Justification Form.</u>

If the candidate has evidence of:	Then this status is valid:
<u>Recurrent bacteremia that recurs from the same organism within four weeks following antibiotic treatment to which the bacteria is susceptible</u>	<u>For 90 days from submission of the Heart Status 3 Justification Form.</u>
<u>Positive culture of material from the pump pocket of an implanted device</u>	<u>For 90 days from submission of the Heart Status 3 Justification Form.</u>

483
484
485
486
487
488
489
490
491
492
493

6.1.C.vii Mechanical Circulatory Support Device (MCSD) with Mucosal Bleeding

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is admitted to the transplant hospital that registered the candidate on the waiting list, is supported by an MCSD, has been hospitalized for mucosal bleeding at least two times within the past six months, excluding the candidate's hospitalization for implantation of the MCSD, and meets at least one of the requirements according to Table 6-2: Evidence of Mucosal Bleeding below.

Table 6-2: Evidence of Mucosal Bleeding

If all of the following occurred:	Then this status is valid for either:
<ol style="list-style-type: none"> 1. <u>The candidate received blood transfusions of at least two units of packed red blood cells per hospitalization during at least two hospitalizations for mucosal bleeding</u> 2. <u>The candidate's international normalized ratio (INR) was less than 3.0 at the time of at least one of the bleeds</u> 3. <u>The candidate's hematocrit upon admission is less than or equal to 0.20 or decreased by 20 percent or more relative to the last measured value at any time during the bleeding episode</u> 	<ul style="list-style-type: none"> • <u>14 days from submission of the Heart Status 3 Justification Form, if the candidate has been hospitalized for mucosal bleeding at least two times within the past six months</u> • <u>90 days from submission of the Heart Status 3 Justification Form, if the candidate has been hospitalized at least three times within the past six months</u>

494
495
496
497

6.1.C.viii Mechanical Circulatory Support Device (MCSD) with Aortic Insufficiency (AI)

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is supported by an MCSD and is not exhibiting evidence of device malfunction, but is experiencing AI, with all of the following:

498
499
500
501
502
503
504
505

1. At least moderate AI by any imaging modality in the setting of the mean arterial pressure (MAP) less than or equal to 80 mm Hg
2. Pulmonary capillary wedge pressure greater than 20 mm Hg
3. New York Heart Association (NYHA) Class III-IV symptoms

506
507
508
509

This status is valid for up to 90 days from submission of the Heart Status 3 Justification Form. After the initial 90 days, this status can be extended by the transplant program every 90 days by submission of another Heart Status 3 Justification Form.

510
511

6.1.C.ix VA ECMO after 14 Days

512
513
514
515
516

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is admitted to the transplant hospital that registered the candidate on the waiting list, is supported by VA ECMO, and has already assigned the candidate to status 1 according to Policy 6.1.A.i: Veno-Arterial Extracorporeal Membrane Oxygenation (VA ECMO) for 14 days.

517
518
519
520
521

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form.

522
523

6.1.C.x Percutaneous Endovascular Circulatory Support Device after 14 Days

524
525
526
527
528

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is admitted to the transplant hospital that registered the candidate on the waiting list, is supported by a percutaneous, endovascular circulatory support device, and has already assigned the candidate to status 2 according to Policy 6.1.B.iv: Percutaneous Endovascular Mechanical Circulatory Support Device for 14 days.

529
530
531
532
533

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form.

534

6.1.C.xi Intra-Aortic Balloon Pump (IABP) after 14 Days

535
536
537
538

A candidate's transplant program may assign a candidate to adult status 3 if the candidate is admitted to the transplant hospital that registered the candidate on the waiting list, is supported by an IABP, and has already assigned the candidate to status 2 according to Policy 6.1.B.v: Intra-Aortic Balloon Pump (IABP) for 14 days.

539
540
541
542

This status is valid for up to 14 days from submission of the Heart Status 3 Justification Form. After the initial 14 days, this status can be extended by the transplant program every 14 days by submission of another Heart Status 3 Justification Form.

543
544

6.1.D Adult Heart Status 4 Requirements

545
546
547

To assign a candidate adult status 4, the candidate's transplant program must submit a Heart Status 4 Justification Form to the OPTN Contractor. A candidate is not assigned adult status 4 until this form is submitted.

548
549
550
551
552

If the candidate is at least 18 years old at the time of registration then the candidate's transplant program may assign the candidate adult status 4 if the candidate has at least one of the following conditions:

553
554
555
556
557

- Is supported by a dischargeable left ventricular assist device (LVAD), according to Policy 6.1.D.i below.
- Is supported by inotropes without continuous hemodynamic monitoring, according to Policy 6.1.D.ii below.
- Is diagnosed with congenital heart disease, according to Policy 6.1.D.iii below.

- 558 • Is diagnosed with ischemic heart disease with intractable angina, according to Policy 6.1.D.iv
559 below.
- 560 • Is diagnosed with amyloidosis, hypertrophic cardiomyopathy or restrictive cardiomyopathy,
561 according to Policy 6.1.D.v below.
- 562 • Is a re-transplant, according to Policy 6.1.D.vi below.
563

564 **6.1.D.i Dischargeable Left Ventricular Assist Device (LVAD)**
565 **without Discretionary 30 Days**

566 A candidate's transplant program may assign a candidate to adult status 4 if the
567 candidate is supported by a dischargeable LVAD. The OPTN Contractor maintains a
568 list of OPTN-approved, qualifying devices.
569

570 This status is valid for up to 90 days from submission of the Heart Status 4
571 Justification Form. After the initial 90 days, this status can be extended by the
572 transplant program every 90 days by submission of another Heart Status 4
573 Justification Form.

574 **6.1.D.ii Inotropes without Hemodynamic Monitoring**

575 A candidate's transplant program may assign a candidate to adult status 4 if the
576 candidate is supported by a continuous infusion of a positive inotropic agent, and
577 meets all of the following:

- 578 1. Cardiac index of <2.2 L/min/m² for candidates without inotropic or mechanical
579 support within 7 days prior to inotrope administration
- 580 2. Pulmonary Capillary Wedge Pressure >15 mmHg
- 581 3. Requires at least one of the following intravenous inotropes:
 - 582 ○ Dobutamine greater than or equal to 3 mcg/kg/min
 - 583 ○ Milrinone greater than or equal to 0.25 mcg/kg/min
 - 584 ○ Epinephrine greater than or equal to 0.01 mcg/kg/min
 - 585 ○ Dopamine greater than or equal to 3 mcg/kg/min

586 This status is valid for up to 90 days from submission of the Heart Status 4
587 Justification Form. After the initial 90 days, this status can be extended by the
588 transplant program every 90 days by submission of another Heart Status 4
589 Justification Form.
590
591

592 **6.1.D.iii Congenital Heart Disease**

593 A candidate's transplant program may assign a candidate to adult status 4 if the
594 candidate is diagnosed with a hemodynamically significant congenital heart disease.
595 The OPTN Contractor maintains a list of OPTN-approved qualifying congenital heart
596 disease diagnoses.
597

598 This status is valid for up to 90 days from submission of the Heart Status 4
599 Justification Form. After the initial 90 days, this status can be extended by the
600 transplant program every 90 days by submission of another Heart Status 4
601 Justification Form.
602

603 **6.1.D.iv Ischemic Heart Disease with Intractable Angina**

604 A candidate's transplant program may assign a candidate to adult status 4 if the
605 candidate is diagnosed with ischemic heart disease and has intractable angina, with
606 all of the following:
607

- 608
609
610
611
612
1. Coronary artery disease
 2. Canadian Cardiovascular Society Grade IV angina pectoris that cannot be treated by a combination of medical therapy, and percutaneous or surgical revascularization
 3. Myocardial ischemia shown by imaging

613
614
615
616
617
618

This status is valid for up to 90 days from submission of the Heart Status 4 Justification Form. After the initial 90 days, this status can be extended by the transplant program every 90 days by submission of another Heart Status 4 Justification Form.

619
620

6.1.D.v Amyloidosis, or Hypertrophic or Restrictive Cardiomyopathy

621
622
623

A candidate's transplant program may assign a candidate to adult status 4 if the candidate is diagnosed with amyloidosis, hypertrophic cardiomyopathy or restrictive cardiomyopathy, with at least one of the following:

- 624
625
626
627
628
629
630
631
632
633
634
- Canadian Cardiovascular Society Grade IV angina pectoris that cannot be controlled by medical therapy
 - NYHA Class III-IV symptoms with either:
 - Cardiac index less than 2.2 L/min/m²
 - Left or right atrial pressure, left or right ventricular end-diastolic pressure, or pulmonary capillary wedge pressure greater than 20 mm Hg
 - Ventricular tachycardia lasting at least 30 seconds
 - Ventricular fibrillation
 - Ventricular arrhythmia requiring electrical cardioversion
 - Sudden cardiac death

635
636
637
638

This status is valid for up to 90 days from submission of the Heart Status 4 Justification Form. After the initial 90 days, this status can be extended by the transplant program every 90 days by submission of another Heart Status 4 Justification Form.

639
640

6.1.D.vi Re-transplant

641
642
643
644

A candidate's transplant program may assign a candidate to adult status 4 if the candidate has a previous heart transplant, and there is evidence of International Society of Heart and Lung Transplantation (ISHLT) coronary allograft vasculopathy (CAV) grade 2-3, or NYHA Class III-IV heart failure symptoms.

645
646
647
648
649

This status is valid for up to 90 days from submission of the Heart Status 4 Justification Form. After the initial 90 days, this status can be extended by the transplant program every 90 days by submission of another Heart Status 4 Justification Form.

650

6.1.E Adult Heart Status 5 Requirements

651
652
653
654

If the candidate is at least 18 years old at the time of registration then the candidate's transplant program may assign the candidate to adult status 5 if the candidate is registered on the heart waiting list, and is also registered on the waiting list for at least one other organ at the same hospital.

655
656
657
658

This status is valid for up to 90 days from submission of the Heart Status 5 Justification Form as long as the candidate is registered for another organ at the same hospital. After the initial 90 days, this status can be extended by the transplant program every 90 days by submission of

659 another Heart Status 5 Justification Form as long as the candidate is registered for another organ
660 at the same hospital.

661
662

6.1.F Adult Heart Status 6 Requirements

663 If the candidate is at least 18 years old at the time of registration and is suitable for transplant,
664 then the transplant program may assign the candidate to adult status 6.

665
666
667
668
669
670

This status is valid for up to 90 days from submission of the Heart Status 6 Justification Form as
long as the candidate remains suitable for transplant. After the initial 90 days, this status can be
extended by the transplant program every 90 days by submission of another Heart Status 6
Justification Form as long as the candidate remains suitable for transplant.

6.2 Pediatric Status Updates Assignments and Update **Requirements**

673 Heart candidates less than 18 years old at the time of registration may be assigned any of the following:

674
675
676
677
678

- Pediatric status 1A
- Pediatric status 1B
- Pediatric status 2
- Inactive status

679
680
681

A candidate registered on the waiting list before turning 18 years old remains eligible for pediatric status
until the candidate has been removed from the waiting list.

682
683
684
685

If a candidate's medical condition changes and the criteria used to justify that candidate's status is no
longer accurate, then the candidate's transplant program must submit a new heart status justification form
to the OPTN Contractor within 24 hours of the change in medical condition.

686
687

6.4.2DA Pediatric Heart Status 1A Requirements

688 *[Subsequent headings and cross-references to headings affected by the re-numbering of this*
689 *policy will also be changed as necessary.]*
690

6.3 Status Adult and Pediatric Status Exceptions

692 A heart candidate can receive a status by qualifying for an exception according to *Table 6-3* below.
693

Table 6-3: Exception Qualification and Periods

Requested Status:	Qualification:	Initial Review	Duration:	Extensions:
<p>Adult status 1A <u>status 1</u></p>	<p><u>1.</u> Candidate is admitted to the transplant hospital that registered the candidate on the waiting list</p> <p><u>2.</u> Transplant physician believes, using acceptable medical criteria, that a heart candidate has an urgency and potential for benefit comparable to that of other candidates at the requested status <u>status</u></p>	<p>RRBs retrospectively review requests for status 1 <u>Status 1A</u>-exceptions</p>	<p>14 days</p>	<ul style="list-style-type: none"> • Require RRB approval for each successive 14 day period • RRB will review and decide extension requests retrospectively • If no extension request is submitted, the candidate will be assigned adult status 1B
<p>Adult status 2 <u>status 1B</u></p>	<p><u>1.</u> Candidate is <u>admitted to the transplant hospital that registered the candidate on the waiting list</u></p> <p><u>2.</u> Transplant physician believes, using acceptable medical criteria, that a heart candidate has an urgency and potential for benefit comparable to that of other candidates at the requested <u>status</u></p>	<p>RRBs retrospectively review requests for status 2 <u>Status 1B</u> exceptions</p>	<p>Indefinite <u>14 days</u></p>	<ul style="list-style-type: none"> • <u>Require RRB approval for each successive 14 day period</u> • <u>RRB will review and decide extension requests retrospectively</u>
<p><u>Adult status 3</u></p>	<p><u>1.</u> Candidate is <u>admitted to the transplant hospital that registered the candidate on the waiting list</u></p> <p><u>2.</u> Transplant physician believes, using acceptable medical criteria, that a heart candidate has an <u>urgency and potential for benefit comparable to that of other candidates at the requested status</u></p>	<p>RRBs retrospectively review requests for <u>status 3</u> exceptions</p>	<p><u>14 days</u></p>	<ul style="list-style-type: none"> • <u>Require RRB approval for each successive 14 day period</u> • <u>RRB will review and decide extension requests retrospectively</u>

Requested Status:	Qualification:	Initial Review	Duration:	Extensions:
Adult status 4	<u>Transplant physician believes, using acceptable medical criteria, that a heart candidate has an urgency and potential for benefit comparable to that of other candidates at the requested status</u>	<u>RRBs retrospectively review requests for status 4 exceptions</u>	<u>90 days</u>	<ul style="list-style-type: none"> • <u>Require RRB approval for each successive 90 day period</u> • <u>RRB will review and decide extension requests retrospectively</u>
Pediatric status 1A	<ul style="list-style-type: none"> • Candidate is admitted to the transplant hospital that registered the candidate on the waiting list • Transplant physician believes, using acceptable medical criteria, that a heart candidate has an urgency and potential for benefit comparable to that of other candidates at the requested status 	RRBs retrospectively review requests for Status 1A exceptions	14 days	<ul style="list-style-type: none"> • Require RRB approval for each successive 14 day period • RRB will review and decide extension requests retrospectively • If no extension request is submitted, the candidate will be assigned pediatric status 1B
Pediatric status 1B	Transplant physician believes, using acceptable medical criteria, that a heart candidate has an urgency and potential for benefit comparable to that of other candidates at the requested status	RRBs retrospectively review requests for Status 1B exceptions	Indefinite	<ul style="list-style-type: none"> • Not required as long as candidate's medical condition remains the same

695
696
697
698
699

The candidate's transplant physician must submit a justification form to the OPTN Contractor with the requested status and the rationale for granting the status exception.

6.3.A RRB and Committee Review of Status Exceptions

700
701
702
703
704
705
706
707
708
709
710

~~The heart RRB reviews all applications for adult and pediatric status exceptions and extensions retrospectively. If an adult status 1A exception request is not approved by the RRB, the candidate's transplant program may override the decision and list the candidate at the requested status. If a pediatric status 1A or status 1B exception request is not approved by the RRB, the candidate's transplant program may override the decision and list the candidate at the requested status, subject to automatic review by the Thoracic Organ Transplantation Committee. The Thoracic Organ Transplantation Committee may review the RRB's decisions and rationale, and may refer any case to the Membership and Professional Standards Committee (MPSC) for further review.~~

If the candidate is transplanted and the RRB does not approve the initial exception or extension request or any appeal, then the case will be referred to the Thoracic Committee. If the Thoracic

711 Committee agrees with the RRB's decision, then the Thoracic Committee may refer the case to
712 Membership & Professional Standards Committee (MPSC) for review according to Appendix L of
713 the OPTN Bylaws.

714 **6.3.A.i. RRB Appeals**

716 If the RRB denies an exception or extension request, the candidate's transplant program must
717 either appeal to the RRB within 1 day of receiving notification of the RRB denial, or assign the
718 candidate to the status for which the candidate qualifies within one day of receiving notification of
719 the RRB denial.

720 **6.3.A.ii Committee Appeals**

722 If the RRB denies the appeal, the candidate's transplant program must within 1 day of receiving
723 notification of the denied RRB appeal either appeal to the Thoracic Organ Transplantation
724 Committee or assign the candidate to the status for which the candidate qualifies. If the Thoracic
725 Committee agrees with the RRB's decision, the candidate's transplant program must assign the
726 candidate to the status for which the candidate qualifies within 1 day of receiving notification of
727 the denied Committee appeal. If the transplant program does not assign the candidate to the
728 status for which the candidate qualifies within 1 day of receiving notification of the denied
729 Committee appeal, then the Committee will refer the case to the MPSC.

730 **6.3.B Exceptions to Allocation for Sensitized Patients**

731
732
733 A transplant program may allocate a heart to sensitized candidates within a DSA out of sequence
734 within a status as defined in *Policy 6.5: Heart Allocation Classifications and Rankings* if:

- 735
736 1. The candidate's transplant surgeon or physician determines that the candidate's antibodies
737 would react adversely to certain human leukocyte antigens (HLA).
738 2. All heart transplant programs and the OPO within the DSA agree to allocate a heart from a
739 compatible deceased donor to the sensitized candidate.
740 3. The candidate's transplant program, all heart transplant programs, and the OPO within the
741 DSA agree upon the level of sensitization at which a candidate qualifies for the sensitization
742 exception.
743

744 Sensitization alone does not qualify a candidate to be assigned any status exception as
745 described in *Policy 6.3: Adult and Pediatric Status Exceptions* above.
746

747 **6.4 Waiting Time**

748 Waiting time for heart candidates begins when the candidate is first registered as an active heart
749 candidate on the waiting list, and is calculated within each heart status.
750

751 If a candidate's status is upgraded, waiting time accrued while ~~registered at the~~ assigned to a lower status
752 is not transferred to the higher status. Conversely, waiting time accrued while ~~registered~~ assigned at a
753 higher status is transferred to a lower status if the candidate is ~~downgraded~~ assigned to a lower status.
754

755 Waiting time does not accrue while the candidate is inactive.
756

757 **6.5 Heart Allocation Classifications and Rankings**

758 **6.5.C Sorting Within Each Classification**

759 Candidates are sorted within each classification by the total amount of waiting time that the
760 candidate has accumulated at that status, according to Policy 6.4: Waiting Time.

761

762

6.5.D Allocation of Hearts from Donors at Least 18 years Old

763

Hearts from deceased donors at least 18 years old are allocated to candidates according to *Table 6-8* below.

764

Table 6-8: Allocation of Hearts from Deceased Donors At Least 18 Years Old

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
1	<u>OPO's DSA or Zone A</u>	<u>Adult status 1 or pediatric status 1A and primary blood type match with the donor</u>
2	<u>OPO's DSA or Zone A</u>	<u>Adult status 1 or pediatric status 1A and secondary blood type match with the donor</u>
3	<u>OPO's DSA or Zone A</u>	<u>Adult status 2 and primary blood type match with the donor</u>
4	<u>OPO's DSA or Zone A</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
5	<u>OPO's DSA</u>	<u>Adult status 3 or pediatric status 1B and primary blood type match with the donor</u>
6	<u>OPO's DSA</u>	<u>Adult status 3 or pediatric status 1B and secondary blood type match with the donor</u>
7	<u>Zone B</u>	<u>Adult status 1 or pediatric status 1A and primary blood type match with the donor</u>
8	<u>Zone B</u>	<u>Adult status 1 or pediatric status 1A and secondary blood type match with the donor</u>
9	<u>Zone B</u>	<u>Adult status 2 and primary blood type match with the donor</u>
10	<u>Zone B</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
11	<u>OPO's DSA</u>	<u>Adult status 4 and primary blood type match with the donor</u>
12	<u>OPO's DSA</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
13	<u>Zone A</u>	<u>Adult status 3 or pediatric status 1B and primary blood type match with the donor</u>
14	<u>Zone A</u>	<u>Adult status 3 or pediatric status 1B and secondary blood type match with the donor</u>
15	<u>OPO's DSA</u>	<u>Adult status 5 and primary blood type match with the donor</u>
16	<u>OPO's DSA</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
17	<u>Zone B</u>	<u>Adult status 3 or pediatric status 1B and primary blood type match with the donor</u>
18	<u>Zone B</u>	<u>Adult status 3 or pediatric status 1B and secondary blood type match with the donor</u>
19	<u>OPO's DSA</u>	<u>Adult status 6 or pediatric status 2 and primary blood type match with the donor</u>
20	<u>OPO's DSA</u>	<u>Adult status 6 and pediatric status 2 and secondary blood type match with the donor</u>
21	<u>Zone C</u>	<u>Adult status 1 or pediatric status 1A and primary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
<u>22</u>	<u>Zone C</u>	<u>Adult status 1 or pediatric status 1A and secondary blood type match with the donor</u>
<u>23</u>	<u>Zone C</u>	<u>Adult status 2 and primary blood type match with the donor</u>
<u>24</u>	<u>Zone C</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
<u>25</u>	<u>Zone C</u>	<u>Adult status 3 or pediatric status 1B and primary blood type match with the donor</u>
<u>26</u>	<u>Zone C</u>	<u>Adult status 3 or pediatric status 1B and secondary blood type match with the donor</u>
<u>27</u>	<u>Zone A</u>	<u>Adult status 4 and primary blood type match with the donor</u>
<u>28</u>	<u>Zone A</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
<u>29</u>	<u>Zone A</u>	<u>Adult status 5 and primary blood type match with the donor</u>
<u>30</u>	<u>Zone A</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
<u>31</u>	<u>Zone A</u>	<u>Adult status 6 or pediatric status 2 and primary blood type match with the donor</u>
<u>32</u>	<u>Zone A</u>	<u>Adult status 6 or pediatric status 2 and secondary blood type match with the donor</u>
<u>33</u>	<u>Zone D</u>	<u>Adult status 1 or pediatric status 1A and primary blood type match with the donor</u>
<u>34</u>	<u>Zone D</u>	<u>Adult status 1 or pediatric status 1A and secondary blood type match with the donor</u>
<u>35</u>	<u>Zone D</u>	<u>Adult status 2 and primary blood type match with the donor</u>
<u>36</u>	<u>Zone D</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
<u>37</u>	<u>Zone D</u>	<u>Adult status 3 or pediatric status 1B and primary blood type match with the donor</u>
<u>38</u>	<u>Zone D</u>	<u>Adult status 3 or pediatric status 1B and secondary blood type match with the donor</u>
<u>39</u>	<u>Zone B</u>	<u>Adult status 4 and primary blood type match with the donor</u>
<u>40</u>	<u>Zone B</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
<u>41</u>	<u>Zone B</u>	<u>Adult status 5 and primary blood type match with the donor</u>
<u>42</u>	<u>Zone B</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
<u>43</u>	<u>Zone B</u>	<u>Adult status 6 or pediatric status 2 and primary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
<u>44</u>	<u>Zone B</u>	<u>Adult status 6 or pediatric status 2 and secondary blood type match with the donor</u>
<u>45</u>	<u>Zone E</u>	<u>Adult status 1 or pediatric status 1A and primary blood type match with the donor</u>
<u>46</u>	<u>Zone E</u>	<u>Adult status 1 or pediatric status 1A and secondary blood type match with the donor</u>
<u>47</u>	<u>Zone E</u>	<u>Adult status 2 and primary blood type match with the donor</u>
<u>48</u>	<u>Zone E</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
<u>49</u>	<u>Zone E</u>	<u>Adult status 3 or pediatric status 1B and primary blood type match with the donor</u>
<u>50</u>	<u>Zone E</u>	<u>Adult status 3 or pediatric status 1B and secondary blood type match with the donor</u>
<u>51</u>	<u>Zone C</u>	<u>Adult status 4 and primary blood type match with the donor</u>
<u>52</u>	<u>Zone C</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
<u>53</u>	<u>Zone C</u>	<u>Adult status 5 and primary blood type match with the donor</u>
<u>54</u>	<u>Zone C</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
<u>55</u>	<u>Zone C</u>	<u>Adult status 6 or pediatric status 2 and primary blood type match with the donor</u>
<u>56</u>	<u>Zone C</u>	<u>Adult status 6 or pediatric status 2 and secondary blood type match with the donor</u>
<u>57</u>	<u>Zone D</u>	<u>Adult status 4 and primary blood type match with the donor</u>
<u>58</u>	<u>Zone D</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
<u>59</u>	<u>Zone D</u>	<u>Adult status 5 and primary blood type match with the donor</u>
<u>60</u>	<u>Zone D</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
<u>61</u>	<u>Zone D</u>	<u>Adult status 6 or pediatric status 2 and primary blood type match with the donor</u>
<u>62</u>	<u>Zone D</u>	<u>Adult status 6 or pediatric status 2 and secondary blood type match with the donor</u>
<u>63</u>	<u>Zone E</u>	<u>Adult status 4 and primary blood type match with the donor</u>
<u>64</u>	<u>Zone E</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
<u>65</u>	<u>Zone E</u>	<u>Adult status 5 and primary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
66	<u>Zone E</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
67	<u>Zone E</u>	<u>Adult status 6 or pediatric status 2 and primary blood type match with the donor</u>
68	<u>Zone E</u>	<u>Adult status 6 or pediatric status 2 and secondary blood type match with the donor</u>

766
767

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
1	<u>OPO's DSA</u>	<u>Adult or pediatric status 1A and primary blood type match with the donor</u>
2	<u>OPO's DSA</u>	<u>Adult or pediatric status 1A and secondary blood type match with the donor</u>
3	<u>OPO's DSA</u>	<u>Adult or pediatric status 1B and primary blood type match with the donor</u>
4	<u>OPO's DSA</u>	<u>Adult or pediatric status 1B and secondary blood type match with the donor</u>
5	<u>Zone A</u>	<u>Adult or pediatric status 1A and primary blood type match with the donor</u>
6	<u>Zone A</u>	<u>Adult or pediatric status 1A and secondary blood type match with the donor</u>
7	<u>Zone A</u>	<u>Adult or pediatric status 1B and primary blood type match with the donor</u>
8	<u>Zone A</u>	<u>Adult or pediatric status 1B and secondary blood type match with the donor</u>
9	<u>OPO's DSA</u>	<u>Adult or pediatric status 2 and primary blood type match with the donor</u>
10	<u>OPO's DSA</u>	<u>Adult or pediatric Status 2 and secondary blood type match with the donor</u>
11	<u>Zone B</u>	<u>Adult or pediatric status 1A and primary blood type match with the donor</u>
12	<u>Zone B</u>	<u>Adult or pediatric status 1A and secondary blood type match with the donor</u>
13	<u>Zone B</u>	<u>Adult or pediatric status 1B and primary blood type match with the donor</u>
14	<u>Zone B</u>	<u>Adult or pediatric status 1B and secondary blood type match with the donor</u>
15	<u>Zone A</u>	<u>Adult or pediatric status 2 and primary blood type match with the donor</u>
16	<u>Zone A</u>	<u>Adult or pediatric status 2 and secondary blood type match with the donor</u>
17	<u>Zone B</u>	<u>Adult or pediatric status 2 and primary blood type match with the donor</u>

18	Zone B	Adult or pediatric status 2 and secondary blood type match with the donor
19	Zone C	Adult or pediatric status 1A and primary blood type match with the donor
20	Zone C	Adult or pediatric status 1A and secondary blood type match with the donor
21	Zone C	Adult or pediatric status 1B and primary blood type match with the donor
22	Zone C	Adult or pediatric status 1B and secondary blood type match with the donor
23	Zone C	Adult or pediatric status 2 and primary blood type match with the donor
24	Zone C	Adult or pediatric status 2 and secondary blood type match with the donor
25	Zone D	Adult or pediatric status 1A and primary blood type match with the donor
26	Zone D	Adult or pediatric status 1A and secondary blood type match with the donor
27	Zone D	Adult or pediatric status 1B and primary blood type match with the donor
28	Zone D	Adult or pediatric status 1B and secondary blood type match with the donor
29	Zone D	Adult or pediatric status 2 and primary blood type match with the donor
30	Zone D	Adult or Pediatric Status 2 and secondary blood type match with the donor
31	Zone E	Adult or pediatric status 1A and primary blood type match with the donor
32	Zone E	Adult or pediatric status 1A and secondary blood type match with the donor
33	Zone E	Adult or pediatric status 1B and primary blood type match with the donor
34	Zone E	Adult or pediatric status 1B and secondary blood type match with the donor
35	Zone E	Adult or pediatric status 2 and primary blood type match with the donor
36	Zone E	Adult or pediatric status 2 and secondary blood type match with the donor

768
769
770

6.5.E Allocation of Hearts from Donors Less Than 18 Years Old

A heart from a pediatric donor will be allocated to a pediatric heart candidate by status and geographical location before being allocated to a candidate at least 18 years old according to *Table 6-9* below.

771
772
773
774

Table 6-9: Allocation of Hearts from Donors Less Than 18 Years Old

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
1	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1A and primary blood type match with the donor</u>
2	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1A and secondary blood type match with the donor</u>
3	<u>OPO's DSA</u>	<u>Adult status 1 and primary blood type match with the donor</u>
4	<u>OPO's DSA</u>	<u>Adult status 1 and secondary blood type match with the donor</u>
5	<u>OPO's DSA</u>	<u>Adult status 2 and primary blood type match with the donor</u>
6	<u>OPO's DSA</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
7	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1B and primary blood type match with the donor</u>
8	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1B and secondary blood type match with the donor</u>
9	<u>Zone A</u>	<u>Adult status 1 and primary blood type match with the donor</u>
10	<u>Zone A</u>	<u>Adult status 1 and secondary blood type match with the donor</u>
11	<u>Zone A</u>	<u>Adult status 2 and primary blood type match with the donor</u>
12	<u>Zone A</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
13	<u>OPO's DSA</u>	<u>Adult status 3 and primary blood type match with the donor</u>
14	<u>OPO's DSA</u>	<u>Adult status 3 and secondary blood type match with the donor</u>
15	<u>OPO's DSA</u>	<u>Adult status 4 and primary blood type match with the donor</u>
16	<u>OPO's DSA</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
17	<u>OPO's DSA</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
18	<u>OPO's DSA</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
19	<u>Zone A</u>	<u>Adult status 3 and primary blood type match with the donor</u>
20	<u>Zone A</u>	<u>Adult status 3 and secondary blood type match with the donor</u>
21	<u>Zone A</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
22	<u>Zone A</u>	<u>Adult status 4 and secondary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
23	<u>Zone A</u>	<u>Adult status 5 and primary blood type match with the donor</u>
24	<u>Zone A</u>	<u>Adult Status 5 and secondary blood type match with the donor</u>
25	<u>OPO's DSA</u>	<u>Pediatric status 2 and primary blood type match with the donor</u>
26	<u>OPO's DSA</u>	<u>Pediatric status 2 and secondary blood type match with the donor</u>
27	<u>OPO's DSA</u>	<u>Adult status 6 and primary blood type match with the donor</u>
28	<u>OPO's DSA</u>	<u>Adult status 6 and secondary blood type match with the donor</u>
29	<u>Zone B</u>	<u>Pediatric status 1A and primary blood type match with the donor</u>
30	<u>Zone B</u>	<u>Pediatric status 1A and secondary blood type match with the donor</u>
31	<u>Zone B</u>	<u>Adult status 1 and primary blood type match with the donor</u>
32	<u>Zone B</u>	<u>Adult status 1 and secondary blood type match with the donor</u>
33	<u>Zone B</u>	<u>Adult status 2 and primary blood type match with the donor</u>
34	<u>Zone B</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
35	<u>Zone B</u>	<u>Pediatric status 1B and primary blood type match with the donor</u>
36	<u>Zone B</u>	<u>Pediatric status 1B and secondary blood type match with the donor</u>
37	<u>Zone B</u>	<u>Adult status 3 and primary blood type match with the donor</u>
38	<u>Zone B</u>	<u>Adult status 3 and secondary blood type match with the donor</u>
39	<u>OPO's DSA</u>	<u>Pediatric status 2 and primary blood type match with the donor</u>
40	<u>OPO's DSA</u>	<u>Pediatric status 2 and secondary blood type match with the donor</u>
41	<u>OPO's DSA</u>	<u>Adult status 6 and primary blood type match with the donor</u>
42	<u>OPO's DSA</u>	<u>Adult status 6 and secondary blood type match with the donor</u>
43	<u>Zone C</u>	<u>Pediatric status 1A and primary blood type match with the donor</u>
44	<u>Zone C</u>	<u>Pediatric status 1A and secondary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
45	<u>Zone C</u>	<u>Adult status 1 and primary blood type match with the donor</u>
46	<u>Zone C</u>	<u>Adult status 1 and secondary blood type match with the donor</u>
47	<u>Zone C</u>	<u>Adult status 2 and primary blood type match with the donor</u>
48	<u>Zone C</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
49	<u>Zone C</u>	<u>Pediatric status 1B and primary blood type match with the donor</u>
50	<u>Zone C</u>	<u>Pediatric status 1B and secondary blood type match with the donor</u>
51	<u>Zone C</u>	<u>Adult status 3 and primary blood type match with the donor</u>
52	<u>Zone C</u>	<u>Adult status 3 and secondary blood type match with the donor</u>
53	<u>Zone C</u>	<u>Adult status 4 and primary blood type match with the donor</u>
54	<u>Zone C</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
55	<u>Zone C</u>	<u>Adult status 5 and primary blood type match with the donor</u>
56	<u>Zone C</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
57	<u>Zone C</u>	<u>Pediatric status 2 and primary blood type match with the donor</u>
58	<u>Zone C</u>	<u>Pediatric status 2 and secondary blood type match with the donor</u>
59	<u>Zone C</u>	<u>Adult status 6 and primary blood type match with the donor</u>
60	<u>Zone C</u>	<u>Adult status 6 and secondary blood type match with the donor</u>
61	<u>Zone D</u>	<u>Pediatric status 1A and primary blood type match with the donor</u>
62	<u>Zone D</u>	<u>Pediatric status 1A and secondary blood type match with the donor</u>
63	<u>Zone D</u>	<u>Adult status 1 and primary blood type match with the donor</u>
64	<u>Zone D</u>	<u>Adult status 1 and secondary blood type match with the donor</u>
65	<u>Zone D</u>	<u>Adult status 2 and primary blood type match with the donor</u>
66	<u>Zone D</u>	<u>Adult status 2 and secondary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
67	<u>Zone D</u>	<u>Pediatric status 1B and primary blood type match with the donor</u>
68	<u>Zone D</u>	<u>Pediatric status 1B and secondary blood type match with the donor</u>
69	<u>Zone D</u>	<u>Adult status 3 and primary blood type match with the donor</u>
70	<u>Zone D</u>	<u>Adult status 3 and secondary blood type match with the donor</u>
71	<u>Zone D</u>	<u>Adult status 4 and primary blood type match with the donor</u>
72	<u>Zone D</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
73	<u>Zone D</u>	<u>Adult status 5 and primary blood type match with the donor</u>
74	<u>Zone D</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
75	<u>Zone D</u>	<u>Pediatric status 2 and primary blood type match with the donor</u>
76	<u>Zone D</u>	<u>Pediatric status 2 and secondary blood type match with the donor</u>
77	<u>Zone D</u>	<u>Adult status 6 and primary blood type match with the donor</u>
78	<u>Zone D</u>	<u>Adult status 6 and secondary blood type match with the donor</u>
79	<u>Zone E</u>	<u>Pediatric status 1A and primary blood type match with the donor</u>
80	<u>Zone E</u>	<u>Pediatric status 1A and secondary blood type match with the donor</u>
81	<u>Zone E</u>	<u>Adult status 1 and primary blood type match with the donor</u>
82	<u>Zone E</u>	<u>Adult status 1 and secondary blood type match with the donor</u>
83	<u>Zone E</u>	<u>Adult status 2 and primary blood type match with the donor</u>
84	<u>Zone E</u>	<u>Adult status 2 and secondary blood type match with the donor</u>
85	<u>Zone E</u>	<u>Pediatric status 1B and primary blood type match with the donor</u>
86	<u>Zone E</u>	<u>Pediatric status 1B and secondary blood type match with the donor</u>
87	<u>Zone E</u>	<u>Adult status 3 and primary blood type match with the donor</u>
88	<u>Zone E</u>	<u>Adult status 3 and secondary blood type match with the donor</u>

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
89	<u>Zone E</u>	<u>Adult status 4 and primary blood type match with the donor</u>
90	<u>Zone E</u>	<u>Adult status 4 and secondary blood type match with the donor</u>
91	<u>Zone E</u>	<u>Adult status 5 and primary blood type match with the donor</u>
92	<u>Zone E</u>	<u>Adult status 5 and secondary blood type match with the donor</u>
93	<u>Zone E</u>	<u>Pediatric status 2 and primary blood type match with the donor</u>
94	<u>Zone E</u>	<u>Pediatric status 2 and secondary blood type match with the donor</u>
95	<u>Zone E</u>	<u>Adult status 6 and primary blood type match with the donor</u>
96	<u>Zone E</u>	<u>Adult status 6 and secondary blood type match with the donor</u>

776
777

<u>Classification</u>	<u>Candidates that are within the:</u>	<u>And are:</u>
1	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1A and primary blood type match with the donor</u>
2	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1A and secondary blood type match with the donor</u>
3	<u>OPO's DSA</u>	<u>Adult status 1A and primary blood type match with the donor</u>
4	<u>OPO's DSA</u>	<u>Adult status 1A and secondary blood type match with the donor</u>
5	<u>OPO's DSA or Zone A</u>	<u>Pediatric status 1B and primary blood type match with the donor</u>
6	<u>OPO's DSA or Zone A</u>	<u>Pediatric Status 1B and secondary blood type match with the donor</u>
7	<u>OPO's DSA</u>	<u>Adult Status 1B and primary blood type match with the donor</u>
8	<u>OPO's DSA</u>	<u>Adult Status 1B and secondary blood type match with the donor</u>
9	<u>Zone A</u>	<u>Adult Status 1A and primary blood type match with the donor</u>
10	<u>Zone A</u>	<u>Adult Status 1A and secondary blood type match with the donor</u>
11	<u>Zone A</u>	<u>Adult Status 1B and primary blood type match with the donor</u>
12	<u>Zone A</u>	<u>Adult Status 1B and secondary blood type match with the donor</u>

Classification	Candidates that are within the:	And are:
13	OPO's DSA	Pediatric status 2 and primary blood type match with the donor
14	OPO's DSA	Pediatric status 2 and secondary blood type match with the donor
15	OPO's DSA	Adult status 2 and primary blood type match with the donor
16	OPO's DSA	Adult status 2 and secondary blood type match with the donor
17	Zone B	Pediatric status 1A and primary blood type match with the donor
18	Zone B	Pediatric status 1A and secondary blood type match with the donor
19	Zone B	Adult status 1A and primary blood type match with the donor
20	Zone B	Adult status 1A and secondary blood type match with the donor
21	Zone B	Pediatric status 1B and primary blood type match with the donor
22	Zone B	Pediatric status 1B, secondary blood type match with the donor
23	Zone B	Adult status 1B and primary blood type match with the donor
24	Zone B	Adult status 1B and secondary blood type match with the donor
25	Zone A	Pediatric status 2 and primary blood type match with the donor
26	Zone A	Pediatric status 2 and secondary blood type match with the donor
27	Zone A	Adult status 2 and primary blood type match with the donor
28	Zone A	Adult status 2 and secondary blood type match with the donor
29	Zone B	Pediatric status 2, primary blood type match with the donor
30	Zone B	Pediatric status 2 and secondary blood type match with the donor
31	Zone B	Adult status 2 and primary blood type match with the donor
32	Zone B	Adult status 2 and secondary blood type match with the donor
33	Zone C	Pediatric status 1A and primary blood type match with the donor
34	Zone C	Pediatric status 1A and secondary blood type match with the donor

Classification	Candidates that are within the:	And are:
35	<u>Zone C</u>	Adult status 1A and primary blood type match with the donor
36	<u>Zone C</u>	Adult status 1A and secondary blood type match with the donor
37	<u>Zone C</u>	Pediatric status 1B and primary blood type match with the donor
38	<u>Zone C</u>	Pediatric status 1B and secondary blood type match with the donor
39	<u>Zone C</u>	Adult status 1B and primary blood type match with the donor
40	<u>Zone C</u>	Adult status 1B and secondary blood type match with the donor
41	<u>Zone C</u>	Pediatric status 2 and primary blood type match with the donor
42	<u>Zone C</u>	Pediatric status 2 and secondary blood type match with the donor
43	<u>Zone C</u>	Adult status 2 and primary blood type match with the donor
44	<u>Zone C</u>	Adult status 2 and secondary blood type match with the donor
45	<u>Zone D</u>	Pediatric status 1A and primary blood type match with the donor
46	<u>Zone D</u>	Pediatric status 1A and secondary blood type match with the donor
47	<u>Zone D</u>	Adult status 1A and primary blood type match with the donor
48	<u>Zone D</u>	Adult status 1A and secondary blood type match with the donor
49	<u>Zone D</u>	Pediatric status 1B and primary blood type match with the donor
50	<u>Zone D</u>	Pediatric status 1B and secondary blood type match with the donor
51	<u>Zone D</u>	Adult status 1B and primary blood type match with the donor
52	<u>Zone D</u>	Adult status 1B and secondary blood type match with the donor
53	<u>Zone D</u>	Pediatric status 2 and primary blood type match with the donor
54	<u>Zone D</u>	Pediatric status 2 and secondary blood type match with the donor
55	<u>Zone D</u>	Adult status 2 and primary blood type match with the donor
56	<u>Zone D</u>	Adult status 2 and secondary blood type match with the donor

Classification	Candidates that are within the:	And are:
57	Zone E	Pediatric status 1A and primary blood type match with the donor
58	Zone E	Pediatric status 1A and secondary blood type match with the donor
59	Zone E	Adult status 1A and primary blood type match with the donor
60	Zone E	Adult status 1A and secondary blood type match with the donor
61	Zone E	Pediatric status 1B and primary blood type match with the donor
62	Zone E	Pediatric status 1B and secondary blood type match with the donor
63	Zone E	Adult status 1B and primary blood type match with the donor
64	Zone E	Adult status 1B and secondary blood type match with the donor
65	Zone E	Pediatric status 2 and primary blood type match with the donor
66	Zone E	Pediatric status 2 and secondary blood type match with the donor
67	Zone E	Adult status 2 and primary blood type match with the donor
68	Zone E	Adult status 2 and secondary blood type match with the donor

778
779

6.5.F Allocation of Heart-Lungs

780 When a heart-lung potential transplant recipient (PTR) candidate is offered allocated a heart, the
781 lung from the same deceased donor must be offered allocated to the heart-lung PTR candidate.

782
783 When a heart-lung candidate-PTR is allocated offered a lung, the heart from the same deceased
784 donor must be offered may only be allocated to the heart-lung PTR according to *Table 6-10*
785 *below* candidate if no suitable Status 1A isolated heart candidates are eligible to receive the
786 heart.

787
788
789

Table 6-10: Allocation of Heart-Lungs If PTR is Offered the Lung

<u>When a heart-lung PTR in this geographic area is offered a lung:</u>	<u>The heart from the same deceased donor must only be offered to the heart-lung PTR after the heart has been offered to all</u>	<u>Within this geographic area:</u>
<u>DSA, Zone A</u>	<u>Pediatric status 1A and Adult status 1 or status 2 isolated heart PTRs</u>	<u>DSA, Zone A</u>
<u>Zone B</u>	<u>Pediatric status 1A and Adult status 1 or status 2 isolated heart PTRs</u>	<u>Zone B</u>

<u>When a heart-lung PTR in this geographic area is offered a lung:</u>	<u>The heart from the same deceased donor must only be offered to the heart-lung PTR after the heart has been offered to all</u>	<u>Within this geographic area:</u>
<u>Zone C</u>	<u>Pediatric status 1A and Adult status 1 or status 2 isolated heart PTRs</u>	<u>Zone C</u>
<u>Zone D</u>	<u>Pediatric status 1A and Adult status 1 or status 2 isolated heart PTRs</u>	<u>Zone D</u>
<u>Zone E</u>	<u>Pediatric status 1A and Adult status 1 or status 2 isolated heart PTRs</u>	<u>Zone E</u>

790
791
792
793
794
795
796
797

The blood type matching requirements described in *Policy 6.5.A: Allocation of Hearts by Blood Type* apply to heart-lung candidates when the candidates appear on the heart match run. The blood type matching requirements in *Policy 10.4.B: Allocation of Lungs by Blood Type* applies to heart-lung candidates when the candidates appear on the lung match run.

3.7.B Required Expedited Modifications of Waiting Time

798
799
800
801

An application for waiting time modifications must follow the procedures for expedited modifications of waiting time if it meets *any* of the following criteria according to *Table 3-5* below:

Table 3-5: Applications Requiring Expedited Modifications of Waiting Time

When:	And the candidate is registered for:	And the transplant program is requesting reinstatement of waiting time including:
An error occurred in removing the candidate's waiting list record	The same organ	Time accrued under the previous registration and any time lost by the error.
An error occurred in registering, modifying, or renewing the candidate's waiting list record	Status 1 liver, <u>pediatric status 1A heart, adult status 1, 2, 3, or 4 heart,</u> or priority 1 pediatric lung	Any time lost by the error.
The candidate was removed from the waiting list for medical reasons, other than receiving a transplant	The same organ with the same diagnosis	Time accrued under the previous registration without the time interval when the candidate was removed from the waiting list.
An islet recipient has re-registered on the islet waiting list	An islet infusion	Any previously accrued waiting time according to <i>Policy 11.3.C: Islet Waiting Time Criteria</i> .
The candidate needs a second organ	Heart, liver, or lung	Modified waiting time for the second organ that includes the waiting time accrued for the first organ.

When:	And the candidate is registered for:	And the transplant program is requesting reinstatement of waiting time including:
The candidate needs a second organ, routine alternative therapies are not possible, and the other transplant programs within the OPO and the OPO itself agree to the modified waiting time	Kidney, pancreas, or intestine	Modified waiting time for the second organ that includes the waiting time for the first organ.

802
803
804
805
806
807
808
809
810
811
812
813
814
815

Additionally, applications must meet any additional requirements outlined in the organ-specific allocation policies. If an application does not comply with the requirements of *Policy 3.7: Waiting Time Modifications*, then the OPTN Contractor will not implement the requested waiting time modifications or forward the application for review.

Applications eligible for expedited modifications of waiting time must use the following process:

1. Upon receipt of a complete application, including the name and signature of the candidate's physician or surgeon, the OPTN Contractor will implement the waiting time modification.
2. The OPTN Contractor will report the modification, without person-identified data, to the relevant organ-specific Committee.
3. The Committee will report the modification, without person-identified data, to the Board of Directors.

816
817
818
819

OPTN Bylaws

820
821

Appendix K K.5 Transition Plan during Long-term Inactivity, Termination, or Withdrawal

822
823
824

When a member transplant hospital experiences long-term inactivity, withdraws its designated transplant program status, or its designated transplant program status is terminated, it must:

825
826
827
828
829

1. Immediately suspend organ transplantation for the transplant program.
2. Assist potential candidates and candidates in transferring to other designated transplant programs.
3. Provide a list to the OPTN Contractor of all of the transplant program's candidates on the waiting list at the time of long-term inactivity, withdrawal, or termination and update it throughout this process. The program should indicate on the list of each candidate if:

830
831
832
833

- A candidate or potential candidate chooses not to transfer to an alternative transplant program, provide the reason and indicate whether the candidate has been completely informed of the implications of this decision before they are removed from the waiting list.

834
835
836
837
838

- A candidate or potential candidate chooses to transfer, indicate the transplant program to which the candidate is transferring. Periodic status updates will be required that documents each candidate's transfer progress until the candidate is evaluated and accepted on the waiting list by another transplant program or removed from the waiting list.

- 839 a. Expedite removal of all candidates from the transplant program's waiting list, or, if the patient
840 requests, transfer the candidate to another OPTN member transplant hospital.
- 841 b. Initiate transfer of all active candidates hospitalized at the transplant program to an accepting
842 transplant hospital within 7 days of long-term inactivity, withdrawal, or termination. The
843 transplant program must complete the transfer process within 14 days unless transfer would
844 be unsafe or discharge is anticipated within that time, or circumstances outside of the
845 program's control exist that prevent transfer within 14 days. The program must document and
846 submit to the OPTN contractor all efforts to transfer its hospitalized candidates, if it is unable
847 to meet these time periods.
- 848 c. Provide a priority list of the most urgent candidates listed at the transplant program with an
849 individualized plan of transfer, potential alternative transplant programs, and a timeline for
850 transferring these candidates according to the following priorities:
- 851
- 852 ■ For liver candidates, all Status 1A and 1B candidates must be transferred within 7 days of
853 long-term inactivity, withdrawal, or termination, followed by all active candidates in
854 descending MELD/PELD score order, with all candidates whose MELD/PELD score
855 exceeds 25 to be transferred within 30 days, followed by all inactive candidates.
 - 856 ■ For lung candidates, active candidates should be transferred according to descending
857 Lung Allocation Scores with highest scores first, followed by inactive candidates.
 - 858 ■ For kidney candidates, those whose PRA (measured or calculated) is over 80 percent
859 should be transferred first, followed by all other active candidates in order of waiting time,
860 then transfer of all inactive candidates last.
 - 861 ■ For heart candidates, all pediatric status 1A and 1B and adult status 1, 2, 3 and 4 must
862 be transferred within 7 days of long-term inactivity, withdrawal, or termination.
 - 863 ■ For multi-visceral organ transplant candidates, transfer must be completed within 30 days
864 of long-term inactivity, withdrawal, or termination.
 - 865 ■ All active candidates should be transferred within 60 days of long-term inactivity,
866 withdrawal, or termination without considering these guidelines.
 - 867 ■ The program must document and submit to the OPTN Contractor all efforts made for
868 transfer of its candidates if it is unable to meet these deadlines.
 - 869 ■ Document all efforts to transfer candidates to an alternative designated transplant
870 program including all contacts made to facilitate the transfer of candidates.
 - 871 ■ Remove every transplant candidate from the transplant program's waiting list within 12
872 months of the program's long-term inactivity, withdrawal, or termination date.

873

874 A member that experiences long-term inactivity, withdrawal, or termination of a designated
875 transplant program may still have the ability to temporarily provide care to transplant candidates,
876 and provide follow-up care as necessary to transplant recipients and living donors. Should the
877 transplant program continue to provide follow-up care to transplant recipients and living donors,
878 the program must continue to submit OPTN follow up forms through UNetSM. Alternatively,
879 transplant recipients may transfer care to another hospital.

880
881

882 **Appendix M: Definitions**

883

884 **Regional Review Boards (RRBs)**

885 Peer review panels established in each of the 11 regions to review all urgent status listings for ~~liver and~~
886 heart candidates. The RRB reviews justification forms submitted by each ~~center~~ transplant hospital
887 documenting the severity of the candidate's illness and justifies the status at which the candidate is listed.
888 ~~Liver RRBs review listings for all liver candidates in Status 1, special case exceptions for MELD/PELD~~
889 ~~liver candidates, and hepatocellular carcinoma (HCC) candidates. Thoracic Heart RRBs review listings~~
890 ~~exception requests for heart candidates in pediatric Status 1A and 1B heart candidates and adult status~~
891 ~~1, 2, 3, and 4 and special case heart candidates in pediatric 1B.~~ These boards also consider appeals of
892 cases initially refused for a particular medical urgency status.

893

#

Appendix A: Comparison of January 2016 Public Comment Proposal with August 2016 Public Comment Proposal

Topic	January 2016 Proposal	Current Proposal
<p>Evidence of Cardiogenic Shock</p>	<p>To qualify for status 2 with acute circulatory support devices, or IAPB, the transplant program must show proof that these therapies were employed to treat cardiogenic shock, evidenced by a cardiac index ≤ 2.2 L/min/m²</p>	<p>Transplant program must show proof that VA ECMO, IABP, percutaneous devices, and multiple inotropes with hemodynamic monitoring are being used to treat cardiogenic shock, evidenced by:</p> <ol style="list-style-type: none"> 1. Systolic blood pressure <90 mmHg 2. Cardiac index <1.8 L/min/m² if the candidate is not supported by inotropes or <2.0 L/min/m² if the candidate is supported by at least one inotrope 3. Pulmonary capillary wedge pressure >15 mmHg <p>If those measures could not be obtained prior to deployment of those therapies, then the transplant program must show at least one of the following was true within 24 hours prior to use of that therapy:</p> <ol style="list-style-type: none"> 1. CPR was performed on the candidate 2. Systolic blood pressure <70 mmHg 3. Arterial lactate >4 mmol/L 4. Aspartate transaminase (AST) or alanine transaminase (ALT) > 1,000 U/L
<p>VA ECMO</p>	<p>Initial qualifying criteria for status 1: candidate is admitted to the hospital and supported by VA ECMO</p> <p>Duration: up to 14 days</p> <p>Extensions: permissible if candidate is still supported by VA ECMO</p>	<p>Initial qualifying criteria for status 1: candidate is admitted to the hospital and supported by VA ECMO for cardiogenic shock (see evidence of cardiogenic shock above)</p> <p>Duration: up to 14 days</p> <p>Extensions: must apply to the RRB to extend, with evidence that candidate has contraindication to transitioning to durable support, and failed weaning off VA ECMO, evidenced by at least one of the following:</p> <ul style="list-style-type: none"> • Mean arterial pressure (MAP) < 60 mmHg • Cardiac index <2.0 L/min/ m2 • Pulmonary capillary wedge pressure >15 • SvO₂ <50% measured by central venous catheter

Topic	January 2016 Proposal	Current Proposal
Continuous mechanical ventilation	Candidates qualify for status 1 if supported by continuous mechanical ventilation	Continuous mechanical ventilation is removed as a status criterion. Candidates must qualify under other options.
Non-Dischargeable VADs	<p>Candidates qualify for status 1 if admitted to the hospital and supported by a surgically implanted, non-dischargeable VAD.</p> <p>Non-dischargeable refers to devices that are not FDA approved for use outside the hospital.</p>	<p>Candidates qualify for status 1 if admitted to the hospital and supported by a non-dischargeable, surgically implanted, non-endovascular BiVAD.</p> <p>Candidates admitted to the hospital and supported by non-dischargeable, surgically implanted, non-endovascular LVADs would qualify for status 2.</p> <p>Non-dischargeable refers to devices that are not FDA approved for use outside the hospital.</p>
IABP	<p>Initial qualifying criteria for status 2: candidate is admitted to the hospital and supported by IABP for cardiogenic shock, evidenced by cardiac index ≤ 2.2 L/m/m²</p> <p>Duration: up to 14 days</p> <p>Extensions: permissible if candidate is still supported by IABP</p>	<p>Initial qualifying criteria for status 2: candidate is admitted to the hospital and supported by IABP for cardiogenic shock (see evidence of cardiogenic shock above)</p> <p>Duration: up to 14 days</p> <p>Extensions: must apply to the RRB to extend, with evidence that candidate has contraindication to transitioning to durable support, and failed weaning off IABP, evidenced by at least one of the following:</p> <ul style="list-style-type: none"> • Mean arterial pressure (MAP) < 60 mmHg • Cardiac index <2.0 L/min/ m2 • Pulmonary capillary wedge pressure >15 • SvO₂ <50% measured by central venous catheter

Topic	January 2016 Proposal	Current Proposal
<p>Acute/ Percutaneous Devices</p>	<p>Initial qualifying criteria for status 2: candidate is admitted to the hospital and supported by an acute circulatory support device for cardiogenic shock, evidenced by cardiac index ≤ 2.2 L/m/m²</p> <p>Duration: up to 14 days</p> <p>Extensions: permissible if candidate is still supported by an acute circulatory support device</p>	<p>Initial qualifying criteria for status 2: candidate is admitted to the hospital and supported by a percutaneous endovascular mechanical circulatory support device without an oxygenator for cardiogenic shock (see evidence of cardiogenic shock above)</p> <p>Duration: up to 14 days</p> <p>Extensions: must apply to the RRB to extend, with evidence that candidate has contraindication to transitioning to durable support, and failed weaning off the device, evidenced by at least one of the following:</p> <ul style="list-style-type: none"> • Mean arterial pressure (MAP) < 60 mmHg • Cardiac index <2.0 L/min/ m2 • Pulmonary capillary wedge pressure >15 • SvO₂ <50% measured by central venous catheter

<p>Multiple Inotropes with hemodynamic monitoring</p>	<p>Initial qualifying criteria for status 3: candidate is admitted to the hospital, and is:</p> <ul style="list-style-type: none"> monitored through an invasive PA catheter or daily hemodynamic monitoring to measure cardiac output and LV filling pressures supported either by a continuous infusion of a high dose intravenous inotrope or multiple inotropes. <p>Duration: up to 14 days</p> <p>Extensions: permissible if candidate remains in the hospital and supported by the inotropes and at least one of the following is true:</p> <ul style="list-style-type: none"> Has an invasive pulmonary artery catheter Cardiac index less than 2.2 L/min/m² on the current medical regimen Failed attempt to wean the inotrope support documented by one of the following: <ul style="list-style-type: none"> Cardiac index less than 2.2 L/min/m² during dose reduction Increase in serum creatinine by 20% over the value immediately prior to, and within 24 hours of, inotrope dose reduction Increase in arterial lactate to greater than 2.5 mmol/L 	<p>Initial qualifying criteria for status 3: candidate is admitted to the hospital, and is:</p> <ul style="list-style-type: none"> monitored through an invasive PA catheter or daily hemodynamic monitoring to measure cardiac output and LV filling pressures supported either by a continuous infusion of a high dose intravenous inotrope or multiple inotropes In cardiogenic shock, evidenced by all of the following: <ul style="list-style-type: none"> Systolic blood pressure <90 mmHg Pulmonary Capillary Wedge Pressure >15 mmHg Cardiac index of <i>either</i>: <ul style="list-style-type: none"> <1.8 L/min/m² for candidates without inotropic or mechanical support within 7 days prior to inotrope administration <2.2 L/min/m² for candidates with inotropic or mechanical support <p>Duration: up to 14 days</p> <p>Extensions: permissible if candidate remains in the hospital and supported by the inotropes and at least one of the following is true:</p> <ul style="list-style-type: none"> Has an invasive pulmonary artery catheter Cardiac index less than 2.2 L/min/m² on the current medical regimen Failed attempt to wean the inotrope support documented by one of the following: <ul style="list-style-type: none"> Cardiac index less than 2.2 L/min/m² during dose reduction Increase in serum creatinine by 20% over the value immediately prior to, and within 24 hours of, inotrope dose reduction Increase in arterial lactate to greater than 2.5 mmol/L
--	--	--

Topic	January 2016 Proposal	Current Proposal
		<ul style="list-style-type: none"> ○ SvO₂ <50% measured by central venous catheter
Review Boards	Review exception requests from each RRB's own region	Review exception and extension requests from other regions
Geographic Sharing (adult donor sequence)	<ol style="list-style-type: none"> 1. Status 1 adults & status 1A pediatrics in DSA + Zone A 2. Status 1 adults & status 1A pediatrics in Zone B 3. Status 2 adults in DSA + Zone A 4. Status 2 adults in Zone B 5. Status 3 adults & status 1B pediatrics in DSA 6. Status 4 adults in DSA 7. Status 3 adults & status 1B pediatrics in Zone A 8. Status 5 adults in DSA 	<ol style="list-style-type: none"> 1. Status 1 adults & status 1A pediatrics in DSA + Zone A 2. Status 2 adults in DSA + Zone A 3. Status 3 adults & status 1B pediatrics in DSA 4. Status 1 adults & status 1B pediatrics in Zone B 5. Status 2 adults in Zone B 6. Status 4 adults in DSA 7. Status 3 adults & status 1B pediatrics in Zone A 8. Status 5 adults in Zone B
Pediatric donor sequence	Attempted to apply adult geographic sharing sequence to pediatric donor sequence. Status 1B pediatric candidates in Zone A received offers after adult status 3 and 4 candidates in the DSA (creating disadvantage that does not exist in current allocation system)	Sticks more closely with current pediatric donor allocation sequence, maintaining broader sharing through Zone A for pediatric status 1A and 1B candidates and adult status 1 and 2 candidates. Status 1B pediatrics in DSA and Zone A will receive offers before adult status 3 and adult status 4 candidates in the DSA.

Appendix B: List of Data Elements that May Be Predictive of Waiting List Mortality or Post-Transplant Survival & References

List of Data Elements that May Be Predictive of Waiting List Mortality or Post-Transplant Survival
Hemodynamic Data
Central Venous Pressure (CVP)
Pulmonary Artery Systolic Pressure (PASP)
Pulmonary Artery Diastolic Pressure (PADP)
Pulmonary Capillary Wedge Pressure (PCWP)/LVEDP
Cardiac Output
Cardiac Index
Systolic Blood Pressure (SBP)
Diastolic Blood Pressure (DBP)
Invasive pulmonary artery catheter or daily hemodynamic monitoring to measure cardiac output and left ventricular filling pressures?
Were hemodynamic values obtained while the patient was on support?
Vital Signs Date
Resting Heart Rate (on same date as hemodynamic tests)
Mixed venous oxygen saturation (with hemoglobin)
Exercise Testing/Functional Status
Cardiopulmonary Stress Test Date
Peak O ₂ Consumption
RER
VE/VCO ₂
Six Minute Walk Test Results
Heart Failure Severity/End Organ Function
Sodium
Creatinine
Dialysis and type
BUN
Albumin
Serum Total Bilirubin
Serum Glutamic Oxaloacetic Transaminase (SGOT)
Brain Natriuretic Peptide (BNP) (specify)
International Normalized Ratio (INR) (and specify Warfarin)
Arterial lactate
Number of hospital admissions for heart failure over last 12 months
Heart Failure Therapies
Diuretic Dose/frequency
Detailed Inotrope Use
Anti-Arrhythmics
Continuous Mechanical Ventilation
Pulmonary Vasodilators
Sensitization Data
CPRA
PRA Typing Method
MFI Threshold
Operative Risk
Number of Prior Sternotomies

References:

1. Berhane Worku et al, "Predictors of Mortality after Short-Term Ventricular Assist Device Placement," *The Annals of Thoracic Surgery* 92:5 (2011): 1608–13. doi:10.1016/j.athoracsur.2011.06.093.
2. Vivek Rao et al, "Revised Screening Scale to Predict Survival after Insertion of a Left Ventricular Assist Device," *Journal of Thoracic and Cardiovascular Surgery* 125:4 (2003): 855-62. doi:10.1067/mtc.2003.111.
3. Stefan Klotz et al, "Pre-Operative Prediction of Post-VAD Implant Mortality Using Easily Accessible Clinical Parameters," *The Journal of Heart and Lung Transplantation* 29:1 (2010): 45-52. doi:10.1016/j.healun.2009.06.008.
4. Rudolf Berger et al, "B-Type Natriuretic Peptide Predicts Sudden Death in Patients with Chronic Heart Failure," *Circulation* 105:20 (2002): 2392-97. doi:10.1161/01.CIR.0000016642.15031.34.
5. Jacqueline Smits et al, "A Prognostic Model for Predicting Waiting-List Mortality for a Total National Cohort of Adult Heart-Transplant Candidates," *Transplantation* 76:8 (2003):1185-89. doi:10.1097/01.TP.0000091171.82384.33.
6. Ryan Davies et al, "Listing and Transplanting Adults with Congenital Heart Disease," *Circulation* 123:7 (2011): 759-67. doi:10.1161/CIRCULATIONAHA.110.960260.
7. Marco Guazzi et al, "Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure," *Circulation: Heart Failure* 2 (2009): 549-55. doi:10.1161/CIRCHEARTFAILURE.109.881326.
8. Daniel Forman et al, "6-Min Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary Exercise Testing in Ambulatory Outpatients with Systolic Heart Failure," *Journal of the American College of Cardiology* 60:25 (2012): 2653-61. doi:10.1016/j.jacc.2012.08.1010.
9. Jaimin Trivedi et al, "Risk Factors of Waiting List Mortality for Patients Awaiting Heart Transplant," *The Journal of Heart and Lung Transplantation* 35:4S (2016): S214.
10. Chim Lang et al, "Peak Cardiac Power Output, Measured Noninvasively, Is a Powerful Predictor of Outcome in Chronic Heart Failure," *Circulation: Heart Failure* 2 (2009): 33-38. doi:10.1161/CIRCHEARTFAILURE.108.798611.
11. M. Chadi Alraies and Peter Eckman, "Adult Heart Transplant: Indications and Outcomes," *Journal of Thoracic Disease*, 6:8 (2014): 1120-1128. doi:10.3978/j.issn.2072-1439.2014.06.44.
12. Wayne Levy et al, "The Seattle Heart Failure Model: Prediction of Survival in Heart Failure," *Circulation* 113:11 (2006): 1424-33. doi:10.1161/CIRCULATIONAHA.105.584102.
13. Doron Aronson et al, "Elevated Blood Urea Nitrogen Level as a Predictor of Mortality in Patients Admitted for Decompensated Heart Failure," *The American Journal of Medicine* 116(7): (2004): 466-73. doi:10.1016/j.amjmed.2003.11.014.